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Schizophrenia (SCH) spectrum disorders are severe and chronic recurring 
psychotic illnesses that have a strong biological basis (Tamminga & Medoff, 
2000). The illness usually manifests in young adulthood, lasts one’s whole life 
(Pagsberg, 2013), and is characterized by significant impairments in reality 
testing, behavior, and functioning (Heckers et al., 2013). The clinical deteriora-
tion that occurs in SCH may, in effect, begin before the first-episode of psycho-
sis (FEP), thus early disease identification and intervention may favorably alter 
the course and outcome of SCH (Lieberman et al., 2001). To strengthen the 
effectiveness of interventions, a deeper scientific effort is needed to properly 
identify and characterize the entire course of the disease. However, despite 
extensive achievements in recent years, the pathogenesis of the SCH spectrum 
disorders has remained poorly understood, mainly because their pathophysio-
logy is not directly apparent in molecular or histopathologic analyses of the 
human brain (Hayashi-Takagi et al., 2014). Notwithstanding the limitations, 
peripheral blood samples have been used for decades in psychiatric research as 
substitutes for central nervous system (CNS) samples (Hayashi-Takagi et al., 
2014). Immune dysregulation in at least a subgroup of SCH patients has been 
found in numerous studies comparing patients to healthy controls, and results 
have indicated that patients with FEP or chronic stage of the psychotic disorder, 
on a group level, show an imbalance in pro- and anti-inflammatory cytokines 
(interleukin (IL)-1β, interferon (INF)-γ, and IL-6, IL-4, IL-10 among others) as 
well as innate immunity, including the monocyte/macrophage system (Miller et 
al., 2011; Upthegrove et al., 2014; Rodrigues-Amorim et al., 2018; Pillinger et 
al., 2019b; Fraguas et al., 2019). There is a strong influence of pro-inflamma-
tory cytokines on tryptophan/kynurenine metabolism which influences the 
serotonergic and glutamatergic neurotransmission via neuroactive metabolites 
such as kynurenic acid (Leonard et al., 2012; Plitman et al., 2017; Cervenka et 
al., 2017). 
Activation of the immune system in SCH occurs not only in the periphery 
but also in the brain (Khandaker et al., 2015; Müller, 2018). The periphery and 
CNS are connected through immune regulators such as the cytokines and also 
through the endocrine and metabolic systems. Furthermore, it has become in-
creasingly evident that the gut microbiota and the brain communicate in a 
bidirectional manner (Lazar et al., 2019) via various routes including the im-
mune system, tryptophan metabolism, the vagus nerve and the enteric nervous 
system, involving microbial metabolites such as short-chain fatty acids, and 
branched-chain amino acids (Cryan et al., 2019).  
Also, studies have extensively documented the metabolic and bioenergetic 
dysfunctions in SCH and confirmed that the disease might have an intrinsic link 
between obesity, prediabetic markers, in particular impaired glucose tolerance 
and insulin resistance, and type 2 diabetes mellitus (T2DM) (Pillinger et al., 
2019a). Moreover, the adipocytes are producing various signal molecules, such 
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as hormones (adiponectin, leptin, resistin), chemokines, such as monocyte 
chemoattractant protein-1 (MCP-1) and proinflammatory cytokines, including 
tumor necrosis factor (TNF)-α, IL-1β and IL-6, all culminating in a low-grade 
inflammation (Carillo et al., 2018). The inflammation may also be triggered by 
oxidative stress (OxS) (Fraguas et al., 2019), which in turn may lead to mito-
chondrial oxidation dysfunction (Miller et al., 2009; Rollins et al., 2009; Zuc-
coli et al., 2017). Acylcarnitines (ACs) are produced as products of incomplete 
mitochondrial fatty acid oxidation. Bioenergetic alterations defined by ACs 
imbalance have been detected in case of several conditions, including, but not 
limited to, obesity, cardiometabolic disorders and SCH (Schönfeld et al., 2016; 
Lopaschuk, 2016; Cao et al., 2019). 
Previous results indicate that the peripheral markers may change at different 
stages among patients with chronic psychotic disorder, but together suggest that 
the peripheral immune system is over-activated both in individuals undergoing 
their FEP and in people with a chronic stage of the SCH spectrum disorders 
(Goldsmith et al., 2016; Pillinger et al., 2019b).  
Importantly, it should be noted that antipsychotic (AP) drugs can modulate 
components of the metabolic and inflammatory-related pathways (Wang et al., 
2018a). 
Based on the above studies from a wide range of authors, the primary ob-
jective of this dissertation was to examine the profiles of inflammatory and 
metabolic biomarkers in FEP patients before and after AP treatment over a 7-
month observation, as well as in patients with a chronic stage of the SCH 
spectrum disorders, and to study interactions between the immune system and 
metabolic shifts in patients with different stages of SCH spectrum disorders. 
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2. REVIEW OF LITERATURE 
2.1. Common characteristics and the course of  
SCH spectrum disorders 
SCH and other psychotic disorders differ in terms of clinical characteristics, the 
course and severity of the disease from person to person – some only have one 
frank psychotic break during their lifetime while others may experience several 
full-blown psychotic episodes with little recovery between these episodes and a 
deepening decline in functioning (Weinberger & Harrison, 2011). The SCH 
spectrum disorders are described in general by fundamental and characteristic 
distortions of thinking and perception, and by inappropriate or blunted affect. 
Clear consciousness and intellectual capacity are usually maintained although 
certain cognitive deficits may evolve with time (WHO, 2019). 
Psychosis is a syndrome – that is a set of symptoms in which it is hard for 
someone to think clearly, make advisable judgments, understand reality, com-
municate effectively, as well as respond emotionally and behave appropriately 
(Tamminga & Medoff, 2000).  
The combination of psychotic symptoms varies, depending on the individual. 
However, these symptoms could be classified into three dimensions:  
• Positive symptoms – also known as psychotic symptoms (e.g. delusions, 
hallucinations, disorganized speech, grossly disorganized or catatonic beha-
vior, agitation) (WHO, 2019). 
• Negative symptoms are thoughts, feelings, or behaviors normally present but 
are absent or diminished in an individual with a psychotic disorder. Examp-
les of negative symptoms are social withdrawal, apathy, poverty of speech, 
blunted or flat affect, limited emotional expression, anhedonia (i.e., inability 
to experience pleasure), as well as lack of motivation and defects in attention 
control (WHO, 2019).  
• Cognitive symptoms emphasize an “executive dysfunction”, which includes 
problems representing and maintaining goals, allocating attentional re-
sources, evaluating and monitoring performance, and utilizing these skills to 
solve problems (WHO, 2019). 
It has been hypothesized that the SCH spectrum disorders have four stages: (i) 
ultra-high risk (UHR) for psychosis, (ii) prodromal period, (iii) FEP, and (4) 
chronic stage or chronic disability from the disease.  
UHR state of psychosis is based on a combination of moderate psychotic 
symptoms, help-seeking behavior, genetic risk, and social/occupational degra-
dation (Bhavsar et al., 2018). There is evidence of cognitive impairment (defi-
ciency) during the UHR period in adolescents and young people with a family 
history of psychosis or SCH (Bora et al., 2014; Kahn et al., 2015). The appea-
rance of psychosis is usually preceded by a period (weeks, months, 2–5 years) 
(Häfner & Maurer, 2006) of mental and behavioral anomalies, including viola-
tions of the cognitive and emotional spheres, the perception of reality, inter-
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action with society, motivation and sleep. FEP has been defined as a condition 
that meets at least the following criteria: (i) an individual is having a first treat-
ment contact due to psychotic symptoms; (ii) defined duration of antipsychotic 
medication use; (iii) and/or duration of psychosis is specified (Breitborde et al., 
2009). The chronic stage of the SCH spectrum disorders is characterized by 
persistent or repeated exacerbations of psychotic symptoms after a short- or 
long-term remission. The chronic stage may cause disability, complications of 
drug therapy, and lead to unemployment and inability to live independently. 
About 60% of FEP cases become chronic SCH, and approximately 25% will 
recover within the first five or six years (an der Heiden & Häfner, 2000). Meta-
analyses have repeatedly confirmed that SCH is associated with higher-than-
average mortality rates: two or three times higher than in the general population 
(Laursen et al., 2014; Simon et al., 2018). Data obtained from studies inves-
tigating life years lost among patients with SCH indicate a reduction of 13.5 
years in life-span for men and 11.4 years for women (Laursen et al., 2018). The 
causes of death range from suicide and cancer to cardiovascular and respiratory 
diseases, as well as other natural and unnatural causes (Auquier et al., 2007). 
However, nowadays, more and more attention is paid to diabetes, metabolic 
syndrome (MetS) and cardiovascular complications that are widespread in 
patients with SCH and are risk factors for premature mortality (Azad et al., 
2016; Schmitt et al., 2018; Simon et al., 2018). 
 
 
2.2. Epidemiology of SCH spectrum disorders 
The incidence for FEP is estimated at 34 new cases per 100,000 person-years, 
the median age-at-referral for men is 22.5 years and for women 23.4 years, 
whereas the incidence rates are highest for both men and women before 20 
years of age (Kirkbride et al., 2017). The lifetime prevalence of psychotic 
disorders varies widely across studies and is from 2.5% to 3% of all psychotic 
disorders, from 0.9% to 1.2% for SCH, and 0.3% for schizoaffective disorder 
(Perälä et al., 2007; Chang et al., 2017). In addition, point prevalence of SCH 
on adults range from 0.9 to 17.4 per 1000 of the population (Warner & De 
Girolamo, 1995) and the median value per 1000 persons (10-90% quantiles) for 
the distributions for lifetime prevalence is 4.0 (1.6-12.1) (Saha et al., 2005).   
 
 
2.3. Etiopathogenesis of SCH spectrum disorders 
The risk of developing SCH spectrum disorders is associated with a genetic pre-
disposition and environmental impact (Walder et al., 2014). Complex inter-
actions between several external factors that affect the key periods in the 
development of the nervous system may result in a pronounced state of the 
disease (Howes & McCutcheon, 2017; Prata et al., 2017). 
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More than hundred years of research into SCH has not revealed specific 
etiologic factors for the development of the disorder. In modern psychiatry, it is 
considered that SCH is a heterogeneous multifactorial disorder with unknown 
single etiological cause, which is based on a predisposition model to the effect 
of stress (Häfner, 2014; Klengel & Binder, 2015; Howes & McCutcheon, 2017; 
Bolhuis et al., 2019). Impairments in cortical and subcortical circuitry, in-
cluding disturbances in several brain neurochemical and immunological sys-
tems, and molecular mechanisms, appear to be core components of the neuro-
biological basis of SCH (Meyer & Feldon, 2009; Nakazawa et al., 2012; 
Schifani et al., 2017). People with SCH spectrum disorders show abnormalities 
in several organ systems in addition to the CNS (i.e., the immune and cardio-
metabolic systems, and hypothalamic-pituitary-adrenal system) (Pillinger et al., 
2019a). 
 
2.3.1. Biological factors 
2.3.1.1. Genetic factors 
Genetic factors and gene-environment interactions together contribute to over 
80% of the probability for developing SCH (Sullivan et al., 2003; Tandon et al., 
2008). If one of the parents or siblings has the illness, the probability of 
developing the disease is 9%. If both parents have SCH, then the probability of 
getting the disease is 36%. Twin studies of SCH show consistent evidence of 
genetic effect in monozygotic than dizygotic twins, 48% and 17%, respectively 
(Tamminga & Medoff, 2000). 
The summation of data obtained from studies using new genomic techno-
logies confirms that SCH is determined by the interaction of risk genes (Wang 
et al., 2018b). To date, genome-wide association studies (GWAS) of the entire 
genome have revealed 128 associations covering more than 100 different 
genetic loci (Ripke et al., 2014). It also revealed rare, but repetitive, 11 copy 
number variants (CNV) loci, which individually determine the relatively high 
risk of SCH (Malhotra & Sebat, 2012).  
In SCH, 75% of the 108 identified associations covering certain loci are 
protein-coding genes (Ripke et al., 2014). There are associations of the expres-
sion of some genes in the brain that support the currently available hypotheses 
related to the dopamine receptor D2 (DRD2), glutamatergic neurotransmission 
(e.g., GRM3, GRIN2A, SRR, GRIA1) and synaptic plasticity, as well as coding 
for calcium channel subunits (CACNA1C, CACNB2, and CACNA1I) (Heyes et 
al., 2015; Fernández-Montoya et al., 2016; Devor et al., 2017). Furthermore, 
GWAS studies of SCH describe the statistically significant association with 
many highly correlated variants in the major histocompatibility complex 
(MHC), which plays an important role in the immune system and the immune 
system development. This process presupposes a relationship between SCH 
spectrum disorders and the immune system (Ripke et al., 2014). What is more, 
SCH spectrum disorders have been shown to share common risk alleles with 
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other psychiatric disorders, such as bipolar disorder, major depressive disorder, 
autism spectrum disorders and attention deficit hyperactivity disorder (Rees et 
al., 2015). 
At the same time, the studies have confirmed that SCH is highly pleiotropic 
(i.e., multiple effects are produced by a single gene) (Lam et al., 2019; Schrode 
et al., 2019). Epidemiological, clinical and genetic studies suggest high co-
morbidity between SCH spectrum disorders and cardiovascular risk factors (e.g. 
levels of triglycerides (TGs), low- and high-density lipoprotein cholesterols 
(LDL-c and HDL-c)) and MetS, as well as the relationship between body mass 
index (BMI) and immunological parameters (Cheng et al., 2012; Liou et al., 
2012; El-Hadidy et al., 2014; Misiak et al., 2016; Kalelioglu et al., 2017).  
 
2.3.1.2. Neurochemical theory of psychotic disorder 
Neurochemical theory suggests that specific abnormalities in the brain neuro-
transmitter systems may cause different kinds of psychotic symptoms. The key 
role belongs to the excitatory glutamatergic system (Stahl, 2008), the neurons of 
which use more than two-thirds of the energy released during the oxidation of 
glucose in the brain (Rothman et al., 2003). N-methyl-d-aspartate (NMDA) 
receptors are the major subtype of glutamate receptors that participate in rapid 
excitatory synaptic transmission. In addition to binding glutamate, the NMDA 
receptor requires glycine as an endogenous co-agonist for its activation and 
maximizing its conductance (Blanke & VanDongen, 2009). NMDA receptors 
are located in brain circuits that regulate the release of dopamine (Javitt, 2010) 
and dysfunction of the glutamatergic system leads to an imbalance of the dopa-
minergic activity (Javitt, 2010; Rubio et al., 2012), causing alterations in the 
function of other neurotransmitter systems (e.g., serotonin, gamma-amino-
butyric acid (GABA), norepinephrine, acetylcholine) and in the levels of 
various neuropeptides (Brisch et al., 2014). NMDA hypofunction is often seen 
as the basis for positive symptoms, negative symptoms, and cognitive impair-
ment in SCH (Lee & Green, 2016). Hyperfunction of dopaminergic neurotrans-
mission in the mesolimbic pathway leads to positive symptoms and hypo-
function in the mesocortical pathway causes negative symptoms and cognitive 
decline (Stahl, 2008; Owen et al., 2016).  
 
 
2.3.1.3. The role of inflammation in SCH spectrum disorders 
Alterations in the communication pathways between the immune and the ner-
vous system play a crucial role in the initiation and progression of psychotic 
disorders (Khandaker et al., 2014a; Howes & McCutcheon, 2017). The evi-
dence accumulated over the past two decades has shown that there are several 
ways in which systemic inflammation can have a profound effect on brain 
function, leading to changes in mood, cognition, and behavior (Khandaker & 
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Dantzer, 2016). Autoimmune diseases are associated with an increased risk of 
developing SCH and other psychiatric disorders (Khandaker et al., 2014b; 
Wang et al., 2018a).  
There is an imbalance between pro-inflammatory and anti-inflammatory 
cytokines in SCH (Khandaker et al., 2015). Cytokines are signaling molecules 
that synchronize innate and adaptive immunity, affecting many different cells, 
including neurons of the CNS (Upthegrove et al., 2014), taking part in the 
synaptic plasticity of neurons, tissue repair, neurogenesis, and synaptogenesis 
(Altamura et al., 2014; Kakar, 2015). Under normal physiological conditions, 
the peripheral immune system is separated from the CNS by the blood-brain 
barrier (BBB), which is formed by vascular cells (i.e., endothelial cells, peri-
cytes, and smooth muscle cells), glia (i.e., astrocytes, oligodendroglia, and 
microglia) and neurons (Zlokovic, 2011). However, under certain conditions, 
the permeability of the BBB increases and cytokines produced by chronically 
activated macrophages and T-lymphocytes penetrate into the CNS (Prat et al., 
2005; Duarte-Delgado et al., 2019). Researchers have identified altered levels of 
several growth factors, pro- and anti-inflammatory biomarkers, including cyto-
kines, such as IL-6, IL-1β, IL-8, IL-4, IL-10, and interferon (INF)–γ in both the 
brain and peripheral blood in SCH and FEP patients (Watanabe et al., 2010; 
Miller et al., 2011; de Witte et al., 2014; Prata et al., 2017).  
Ligands for ErbB receptors are members of the molecular superfamilies 
represented by epidermal growth factor (EGF) and neuregulins, and are im-
plicated in the etiopathology of SCH (Futamura et al., 2002; Stefansson et al., 
2002). EGF has a neurotransmitter-like or neuromodulatory role in the CNS 
(Yamada et al., 1997). EGF enhances NMDA receptor-mediated increase of the 
intracellular Ca2+ concentration in cultured rat hippocampal neurons (Abe & 
Saito, 1992), protects against the glutamate toxicity-induced death of dopami-
nergic neurons in culture, induces an increase of glutamine synthetase activity 
in astrocytes in vitro, and exhibits a neurotrophic influence on dopaminergic 
neurons (Yamada et al., 1997). There is an evidence that serum EGF levels are 
decreased in patients with SCH (the sample consisted of drug-naïve patients 
n=4 and treated chronic patients n=45) (Futamura et al., 2002). Contrary, Hashi-
moto et al. (2005) found that serum levels of drug-naïve patients (n=15) or 
medicated patients (n=25) with SCH did not differ from those of CSs (n=40). 
However, the EGF level was correlated with the severity of symptoms in 
patients with SCH (Hashimoto et al., 2005). Growth factors have an impact on 
cytokine production and are related to inflammatory responses. The preclinical 
studies suggest that there is an association of EGF with pro‐inflammatory 
cytokines, such as IL‐1β, IL‐6 and TNF‐α, and the anti‐inflammatory cytokine 
IL‐10 (Islam et al., 2016).  
Increased blood levels of IL-6 are one of the most consistently confirmed 
immunological features associated with SCH (Goldsmith et al., 2016; Pillinger 
et al., 2019b; Fraguas et al., 2019). IL-6 has pro- and anti-inflammatory pro-
perties which are context-dependent (Hunter & Jones, 2015). The elevated 
levels of IL-6 are related to the duration of the disorder, the resistance of 
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patients to AP treatment, and can be taken as state markers for acute disease 
exacerbation (Zalcman et al., 1994; Miller et al., 2011). Moreover, there is evi-
dence that IL-6 modulates dopaminergic metabolism and symptomatology in 
SCH (Kim et al., 2000). Furthermore, IL-6 also has a non-immunological and 
non-neurochemical role, such as inducing obesity-related metabolic disorders in 
SCH (Borovcanin et al., 2017).  
IL-1 is a pro-inflammatory cytokine that has neurodegenerative and neuro-
protective properties, and it is involved in the modulation of synaptic plasticity 
as well as stress responses in the brain (Sapolsky, 1987; Giles et al., 2015). 
Although IL-1α and IL-β are encoded by separate genes, they elicit similar 
biological activity (Shaftel et al., 2008). This cytokine strongly modulates the 
release and processing of EGF and neuregulin 1, and exhibits association with 
ErbB signaling (Higashiyama et al., 2008). There are inconsistencies between 
studies concerning IL-1 levels in patients with SCH (Miller et al., 2011; Upthe-
growe et al., 2014; Goldsmith et al., 2016). 
IL-2 influences various lymphocyte subsets during differentiation, immune 
responses, and homeostasis (Boyman & Sprent, 2012). Furthermore, it is a po-
tent modulator of dopamine activity in the mesocorticolimbic and mesostriatal 
systems, and it is also associated with increased motor activity and psycho-
pathological outcomes of SCH, which at least partly reflect aberrations in 
central dopaminergic transmission (Zalcman, 2002). Several studies have re-
ported altered peripheral levels of IL-2 in SCH (Ganguli et al., 1989; Potvin et 
al., 2008).  
IL-8 (or chemokine C-X-C motif ligand 8) is a chemokine produced mainly 
by macrophages. IL-8 production is increased by OxS, which in turn causes the 
recruitment of inflammatory cells and induces a further increase in OxS media-
tors, making it a key parameter in localized inflammation (Vlahopoulos et al., 
1999). IL-8 was also shown to be associated with an increase in BMI (Shara-
biani et al., 2011). In several studies, it has been found that IL-8 levels were 
higher in patients with SCH than those of CSs (Kaminska et al., 2001; Zhang et 
al., 2002).  
IL-10 is a regulatory cytokine, which maintains the balance between pro- 
and anti-inflammatory cytokines (Murray, 2006). Evidence has demonstrated 
that IL-10 is associated with SCH. A meta-analysis of genomic studies demon-
strated that in the Asian population, subjects with a single nucleotide poly-
morphism (rs1800872) and two haplotypes (A-C-A and G-C-C) of IL-10 are 
vulnerable to SCH (Gao et al., 2014). Furthermore, a significant increase of IL-
10 was observed in patients with SCH compared with CSs (Kunz et al., 2011), 
and it has been demonstrated that blood levels of IL-10 are correlated to the 
extent of cognitive impairment in patients with SCH (Xiu et al., 2016).  
IL-4 is an anti-inflammatory cytokine that contributes to the suppression of 
the immune and inflammatory response. Previous results have described 
decreased levels (Kim et al., 2009) or no significant changes in the serum levels 
of IL-4 in SCH patients (Potvin et al., 2008).  
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Studies regarding TNF-α levels in individuals with SCH vary from low 
(Francesconi et al., 2011; Tian et al., 2014) to no difference (Kaminska et al., 
2001; Potvin et al., 2008) to higher levels (Miller et al., 2011; Di Nicola et al., 
2013; Goldsmith et al., 2016). TNF-α is involved in systemic inflammation and 
is produced mainly by activated macrophages, natural killer cells, and lymp-
hocytes. Furthermore, TNF-α is synthesized in adipose tissue by adipocytes and 
data suggests an important role TNF-α holds in the insulin resistance of obesity 
and T2DM (Hotamisligil & Spiegelman 1994).  
Studies suggest that there is a linear relationship of ferritin concentrations 
and acute-phase proteins (DePalma et al., 2010; Namaste et al., 2017). The 
increased plasma ferritin concentration, as a marker of increased iron concentra-
tions, is associated observationally and genetically with low-grade inflamma-
tion, possibly indicating a causal relationship from increased ferritin to inflam-
mation (Moen et al., 2018). 
INF-γ elevations are frequently noted in patients with SCH (Miller et al., 
2011; Pillinger et al., 2019a). INF-γ is produced predominantly by T helper 
cells, macrophages, and natural killer cells as a part of the innate response, and 
it is also an important activator of MHC molecule expression (Billiau, 1996). 
Moreover, INF-γ is a pro-inflammatory cytokine involved in the pathology of 
the neuroinflammatory response and is mostly released from activated microglia 
(Na et al., 2014).  
Activation of the immune system in SCH occurs not only in the periphery 
but also in the brain (Leonard et al., 2012). Inflammation in the CNS is 
mediated by pro-inflammatory cytokines, microglial cells, astrocytes, and 
invading immune cells such as monocytes, macrophages, and T or B lympho-
cytes (Schwarz, 2003). Furthermore, besides the direct action of cytokines on 
brain cells, a biochemical link exists between cytokines and the tryptophan-
kynurenine pathway (Schwarz, 2003). Tryptophan is the precursor of two 
distinct metabolism pathways, leading to the end products of either 5-hydro-
xytryptamine (5-HT) or kynurenine. Enzymes of the kynurenine pathway are 
expressed in different tissues and cell types throughout the body and are 
regulated by cues, including inflammatory signals (Cervenka et al., 2017). By 
the enzymatic action of indoleamine-2,3-dioxygenase (IDO), tryptophan is 
converted into quinolinic acid, a potent neurotoxin, related to NDMA receptor 
activation, and tryptophan-2,3-dioxygenase (TDO) enzymatic activity is related 
to the synthesis of kynurenic acid, an NMDA and nicotine alpha7 receptor 
antagonist (Macedo et al., 2019). Proinflammatory cytokines (e.g., INF-γ, IL-1, 
IL-2, IL-6, TNF-α) can induce IDO activity (Carlin et al., 1989; Leonard et al., 
2012). Thus, as a consequence of this systemic metabolism integration, 
peripheral inflammation can facilitate the accumulation of kynurenine in the 
brain, which has been associated with psychotic symptoms and cognitive 
deficits among patients with SCH (Javitt et al., 2012; Cervenka et al., 2017). 
The kynurenine pathway generates tryptophan metabolites with diverse 
biological activities throughout the body and although mainly studied in relation 
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to the brain and mental health, the action of kynurenine metabolites on peri-
pheral tissues might be even more meaningful (Cervenka et al., 2017).  
However, it has been suggested that there are biological subtypes of SCH 
spectrum disorders (Miller et al., 2009), and that immune alterations are seen 
only in a proportion of patients (Pillinger et al., 2019b).  
 
 
2.3.1.4. Cardiometabolic abnormalities in SCH spectrum disorders 
SCH spectrum disorders are associated with a 2- to 3-fold excess mortality 
(Nielsen et al., 2013; Suvisaari et al., 2013; Termorshuizen et al., 2014) and a 
8‒20-year life span shortening (Chang et al., 2011; Nordentoft et al., 2013). 
Poor physical health has traditionally been referred as a result of secondary im-
pacts of the disease itself, in addition to an unhealthy lifestyle and a poor diet, 
or seen as a consequence of AP treatment (McGreadi et al., 2003; Bressington 
et al., 2016). However, in recent years, studies in drug-naïve FEP patients have 
confirmed that dysfunction in the cardiometabolic system is already present at 
the early stage of the disease (Pillinger et al., 2019a).  
It has been repeatedly confirmed that compared with the general population, 
people with severe mental illness have a higher risk of developing obesity-
related problems such as hypertension, stroke, MetS, and T2DM (Foley & 
Morley, 2011; De Hert et al., 2012; Stubbs et al., 2015). MetS incidence in 
psychiatric patients with FEP has been shown to range between 6.0% and 9.8% 
(Fleischhacker et al., 2013; Mitchell et al., 2013). The incidence of MetS among 
patients with SCH ranges from 24% to 43% in males and from 27% to 52% in 
females (Lin et al., 2018). MetS is a combination of insulin resistance, impaired 
glucose regulation, dyslipidemia, hypertension, microalbuminuria, and obesity 
(Anjum et al., 2018). Obesity occurs when excess energy accumulates in adipo-
cytes and it involves an increase in both the number and the size of fat cells. 
There are three types of adipose tissue: brown, beige and white (Carrillo et al., 
2018). Brown adipose tissue is less abundant and is involved in lipid oxidation 
and energy balance; beige adipose tissue has the pathway of adaptive thermo-
genesis, and white adipose tissue is an endocrine organ that secretes different 
molecules (Carrillo et al., 2018). One of the major features of adipocyte biology 
is the discovery of its complex secretory activities (Lafontan, 2005). Leptin, 
adiponectin, proinflammatory cytokines, acute phase reactant proteins, MCP-1, 
and resistin are of great interest among the growing number of factors found to 
be secreted by adipocyte (Trayhurn & Beattie, 2001; Havel, 2004; Lafontan, 
2005).  
The overexpressed pro-inflammatory cytokines, particularly IL-6, are con-
sidered as the link between obesity and inflammation (Hotamisligil, 2006). It 
has been established that higher plasma levels of IL-6 are significantly cor-
related with an increased amount of adipose tissue and increased BMI (Lee et 
al., 2017) and it has been shown that one-third of total circulating con-
centrations of IL-6 originate from adipose tissue (Fontana et al., 2007). Also, 
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TNF-α has been considered as a key component in the obesity-diabetes link 
(Tzanavari et al., 2010). TNF-α has been suggested to be involved in the 
pathogenesis of SCH. However, this relationship remains controversial (Potvin 
et al., 2008). 
Adiponectin or adipocyte-specific protein is involved in the regulation of 
glucose levels as well as in fatty acid breakdown, and its serum concentrations 
are reduced in a variety of obese and insulin resistance states (Lafontan, 2005). 
Comparative meta-analysis has shown that people with SCH treated with 
second-generation AP treatment have lower plasma adiponectin levels than CSs 
(Bartoli et al., 2015).  
MCP-1 is a potent adipokine. It is considered to be a specific chemo-
attractant for monocytes and macrophages, which may also play a role in the 
development of obesity, diabetes, and cardiovascular diseases (Panee, 2012). 
The elevated level of MCP-1 and its association with MetS in patients with 
SCH has been shown (Drexhage et al., 2008).  
Biologically active procoagulant molecule plasminogen activator inhibitor-1 
(PAI-1) is also produced by adipocytes (Lafontan, 2005). Current evidence 
suggests that PAI-1 plays the central role played in many age-related subclinical 
(i.e., inflammation, atherosclerosis, insulin resistance) and clinical (i.e., obesity, 
comorbidities) conditions (Cesari et al., 2010). Furthermore, there is also 
emerging literature sugesting the plasminogen pathway in SCH (Hoirisch-
Clapauch & Nardi, 2016; Jeffries et al., 2018). 
Leptin is a mediator of long-term regulation of energy balance, controlling 
food intake and thereby inducing weight loss (Klok et al., 2007). Furthermore, 
leptin is a pleiotropic molecule that may regulate neuroendocrine and immune 
functions (Margetic et al., 2002; Havel et al., 2004). Positive effectors of leptin 
production are glucose, insulin, glucocorticoids, and TNF-α, among others (La-
fontan, 2005). Leptin and insulin act synergistically to modulate the central 
regulation of feeding and whole-body energy homeostasis (Niswender & 
Schwartz, 2003). In humans, both high and low levels of leptin have been 
associated with psychopathology of mental disorders (Wędrychowicz et al., 
2014).  
Several studies have identified resistin as the main hormone linking insulin-
resistance to obesity, primarily through the activation of Toll-Like Receptor 4 
signaling pathways (Benomar & Taouis, 2019). Also, resistin is found to be 
associated with acute and chronic inflammatory-related diseases (Pang & Lee, 
2006). Researchers have indicated that the rates of insulin resistance, impaired 
glucose tolerance, and hyperinsulinemia are high in AP-naïve FEP patients, 
patients with a chronic stage of the disease and unaffected relatives of patients 
(Guest, 2019). Furthermore, Tomasik et al. (2019) recently demonstrated that 
SCH polygenic risk score was significantly linked to insulin resistance in AP-
naïve FEP patients regardless of demographic, lifestyle and clinical factors.  
Moreover, it is widely accepted that healthy gut microbiota is essential for 
human health. Studies demonstrate that the microbiota may impact weight gain 
and adiposity through several interconnected pathways, such as energy harvest 
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and production of microbial metabolites, through effects on inflammatory 
responses and the gut-brain axis (Lazar et al., 2019). Preclinical experiments in 
gnotobiotic models of mice and rats revealed the effect of an imbalance of the 
microbiota on the intestinal mucosa and the host immune system (Karlsson et 
al., 2011; Wrzosek et al., 2013). This causes an increase in various immuno-
logical mediators in the intestinal wall, thereby stimulating the body's immune 
system (Okumura & Takeda, 2017) and implicating the presence of low-grade 
inflammation (Cani et al., 2008) and metabolic imbalance (Cani et al., 2007). 
Furthermore, there are significant alterations in the microflora of obese and 
SCH people (Ley et al., 2006; Clemente et al., 2012; Zheng et al., 2019). 
Several mechanisms are responsible for hepatic and muscle insulin resis-
tance (Abel, 2010). These include (i) increased activation of inflammation-
mediated signaling cascades; (ii) lipotoxicity, which can be caused by excessive 
accumulation of TGs and metabolic intermediates, such as diacylglycerols and 
ceramides, which come from saturated fatty acids (Rutkowsky et al., 2014); (iii) 
incomplete mitochondrial β-oxidation of long-chain fatty acids (LCFA), due in 
part to relatively low tricarboxylic acid cycle capacity, which increases tissue 
accumulation of acetyl-coenzyme A (acetyl-CoA) and generates chain-shortened 
AC molecules that activate pro-inflammatory pathways implicated in insulin 
resistance (Adams et al., 2009).  
ACs metabolism is a key factor in regulating the balance of intracellular 
sugar and lipid metabolism (Qu et al., 2016). The metabolism of fatty acids 
(with a long chain) begins in the cytoplasm with the addition of carnitine 
(CARN), then the process of oxidation in the mitochondria of the cells takes 
place according to the β-oxidation (each time the β-carbon atom is oxidized) 
with the active participation of AC located on the surface of the inner 
mitochondrial membrane (Muñiz, 2003; Rosenthal & Glew, 2009; Grevengoed 
et al., 2014). Studies suggest that the long-chain acyl-coenzyme A (acyl-CoA) 
synthetases may play a role in directing fatty acids either toward complex lipid 
synthesis and storage or toward oxidation (Coleman et al., 2002). However, 
blood ACs are indirect indicators of altered β-oxidation of fatty acids (Schoone-
man et al., 2013).  
There is evidence that lipolysis and β-oxidation are activated during SCH, 
probably as a result of insufficient energy supply to the brain (Yang et al., 
2017), which can cause a shift in the profile of ACs and CARN (i.e., the accu-
mulation of species acyl-CoA in mitochondria), causing the CARN shuttle to 
work in reverse order (Knottnerus et al., 2018). ACs profile analysis is a method 
for diagnosing disorders of fatty acid oxidation and metabolic disorders of 
organic acids (Graef et al., 1997; Cao et al., 2019). Thus, mitochondrial dys-
function associated with SCH (Rollins et al., 2009) could be described through 






2.3.2. Psychosocial factors 
Traumatic life events in childhood are a potential risk factor for SCH. Ac-
cording to research data, the risk of developing psychosis in people with a 
history of childhood trauma is almost 3 times higher than in the CSs, while in 
the population this risk is 33% (Şahin et al., 2013). Among prodromal patients, 
70% have a history of traumatic events (Bechdolf et al., 2010), which are 
maltreatment, physical, psychological, and sexual abuse as well as loss or 
divorce of parents in childhood, substance abuse by parents and poverty (Green 
et al., 2014). 
 
 
2.3.3. Environmental factors  
Ecological theories link the genesis of SCH with pre-, peri- and postnatal 
damage to the fetus, which promotes the expression of gene combinations that 
may predispose to SCH (Stilo et al., 2011). The risk of SCH is increased, for 
example, if during pregnancy, the mother suffered an infection of influenza or 
rubella, was malnourished, had diabetes mellitus or smoked (Mueser & 
McGurk, 2004). Those suffering from SCH are more often born in the winter or 
early spring, have a small birth weight, are born in difficult births or suffered a 
CNS lesion or a head injury in early childhood (Tandon et al., 2008). One of the 
alleged pathogenetic mechanisms of SCH is local hypoxia of the brain during 
critical periods in the migration and maturation of neurons (Weinberger & 
Harrison, 2011). 
It is well known that psychostimulants such as amphetamine and meth-
amphetamine increase synaptic dopamine concentrations. Furthermore, the use 
of cannabis is a potential risk factor predisposing to SCH. The findings indicate 
a 40% increase in the likelihood of developing psychosis in cannabis users 
compared to the control group (Manrique-Garcia et al., 2012; Gage et al., 2016; 
Di Forti et al., 2019). The use of cannabis leads to the development of psychosis 
2.7 years earlier compared to those who developed psychosis not having used 
cannabis (Degenhardt et al., 2013). In the GWAS, 35 significant genes were 
identified in 16 regions, whereas 21 of the genes had different levels of expres-
sion in humans using cannabis, the largest correlation in the cell adhesion mole-
cule 2 (CADM2) gene, which demonstrated evidence for a causal positive im-
pact of SCH on cannabis use (Pasman et al., 2018). Furthermore, the evidence 
of gene-environment interaction between the catechol-O-methyltransferase 
(COMT) gene and exposure to cannabis has an important role in dopamine 
metabolism in the prefrontal cortex and other brain regions (Caspi et al., 2005; 
Tunbridge et al., 2006). 
In summary, studies in recent decades have provided ample evidence of the 
importance of inflammatory and metabolic changes in SCH spectrum disorders, 
which affect the course of the disease, the development of side effects of the AP 
treatment, and patients’ quality of life. Immune dysregulation and metabolic 
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alterations have been found in numerous studies comparing AP-naïve or treated 
FEP patients to healthy controls. Meta-analyses have confirmed that patients 
with an SCH spectrum disorder, on a group level, demonstrate signs of the low-
grade peripheral inflammation and metabolic changes. The identification of 
quantifiable biological biomarkers and using these biomarkers in clinical 
practice have great potential for improving diagnostic accuracy, stratifying 
treatment selection, providing prognostic information, monitoring relapse, 
detecting and helping to prevent mental health problems, particularly psychotic 
symptoms before they reach clinical-level symptomatology.  
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3. AIMS OF THE THESIS  
This thesis is based on three empirical articles that explore inflammatory and 
metabolic abnormalities at the beginning and in the chronic stage of the SCH 
spectrum disorders.  
The general thematic research foci were the following: 
1. To evaluate the inflammatory and metabolic biomarker level differences in 
patients with FEP before and after a 7-month treatment with APs as com-
pared to CSs (Paper I).  
2. To characterize a bioenergetic dysfunction through a complex interplay 
between inflammatory and metabolic protein biomarkers as well as ACs 
profiles in patients with FEP before and after a 7-month AP treatment as 
compared to CSs (Paper II).  
3. To identify low-grade inflammatory and metabolic alterations in patients 
with SCH spectrum disorders as compared to CSs (Paper III).  
  
25 
4. SUBJECTS AND METHODS 
The research project was approved by the Ethics Review Committee on Human 
Research, the University of Tartu, Estonia (initial approval No 177/T-2 issued 
on 15 Feb 2008 and follow-up approval No 211/M-22 issued 23 Jan 2012; 
No96/16 issued 21 Aug 2001 and No 176/T-4 issued 17 Nov 2008). Written 
informed consent was obtained from all participants. 
 
Below are visual illustrations of the design of studies: Figure 1 comprises 
participants and methods for FEP patients’ studies, and Figure 2 provides an 
overview of the study on patients with the chronic stage of the disease.  
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ICD-10 – International Classification of Diseases, PANSS – Positive and Negative Syndrome 
Scale, FEP – first-episode psychosis, SCH – schizophrenia, CSs – control subjects, AP – 
antipsychotics, BMI – body mass index, IL – interleukin, CRP – C-reactive protein, TNF-α – 
tumor necrosis factor-α, INF-γ – interferon-γ, VEGF – vascular endothelial growth factor, EGF – 
epidermal growth factor, PAI-1 – plasminogen-activator inhibiitor-1, MCP-1 – monocyte chemo-
attractant protein-1.  
 
Figure 1. Schematic summary of materials and methods for FEP patients’ studies 
(Paper I, II). 
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ICD-10 – International Classification of Diseases, PANSS – Positive and Negative Syndrome 
Scale, FEP – first-episode psychosis, SCH – schizophrenia, CSs – control subjects, AP – 
antipsychotics, BMI – body mass index, IL – interleukin, CRP – C-reactive protein, TNF-α – 
tumor necrosis factor-α, INF-γ – interferon-γ, VEGF – vascular endothelial growth factor, EGF – 
epidermal growth factor, PAI-1 – plasminogen-activator inhibitor-1, MCP-1 – monocyte chemo-
attractant protein-1, TGs – triglycerides, LDL-c – low-density lipoprotein cholesterol, HDL-c – 
high-density lipoprotein cholesterol, HbAc1 – glycated hemoglobin. 
 







The FEP and SCH patients were recruited from the Psychiatric Clinic of the 
Tartu University Hospital, Estonia (Paper I, II, and III) and partially from the 
Võisiku Psychiatric Nursing Home, a state nursing home in central Estonia 
(Paper III). Psychiatric diagnoses were based on clinical interviews according to 
the criteria of the International Classification of Diseases, tenth edition (ICD-
10) (WHO, 1992), and the illness history was confirmed by an examination of 
the patients’ medical records and semi-structured psychiatric interviews. 
 
4.1.1. FEP patients and CSs (Paper I, II) 
38 FEP patients (21 males and 17 females; mean age 25.4±0.9 years) fulfilled 
the following inclusion criteria: they were 18–45 years old; had experienced a 
FEP; duration of their untreated psychosis had been less than 3 years; no AP 
treatment received before the first contact with medical services for psychosis. 
Patients were excluded from the study if they had psychotic disorders addi-
tionally to any other main health condition or had substance-induced psychosis. 
Thirty-six FEP patients underwent treatment using AP medication (two refused) 
and were included in the follow-up analysis. History of AP medication was 
collected according to reviews of patients’ medical charts. Patients were treated 
with various AP medications according to what was clinically indicated, and 
treatment options were allowed to change over the course of the 7-month 
interval. During the follow-up period, patients received either atypical (n=24), 
typical (n=1) or mixed (n=11) AP medication; the theoretical chlorpromazine 
(CPZ) daily dose equivalent means (±sd) was 396 (±154) mg (range from 80 to 
640 mg). Twenty-eight patients were treated only with APs, but 5 patients 
additionally needed mood stabilizers and 6 patients also received antidepres-
sants or hypnotics. Psychopathology was measured using the Positive and 
Negative Syndrome Scale (PANSS) (Kay et al., 1987). Data were collected at 
two time points: on admission and after the follow-up period (mean duration 
7.2±0.7 months). 
Thirty-seven mentally healthy subjects participated in the study as CSs (16 
males and 21 females, mean age 24.8±0.9 years). The CSs sample was recruited 
by advertising in the same geographical area the FEP patients came from. CSs 
were interviewed by experienced psychiatric doctors to avoid the inclusion of 
subjects as controls with mental disorders. Exclusion criteria for the control 
group also included psychotic disorders among close relatives. Data from CSs 





4.1.2. Patients with the chronic stage of the disease and  
CSs (Paper III) 
The total number of patients who agreed to take part and met the inclusion 
criteria was 105 (45 males and 60 females). They were aged 28–74 (53.1±10.9) 
years, with illness duration of 6–52 years (mean 19.9±9.8). They had a stable 
AP medication regimen and sustained clinical status for at least one month 
before entering the study. All the patients were taking AP drugs and some 
received more than one medication, as was clinically indicated. Psychopatho-
logy was measured using the PANSS (Kay et al., 1987). The following AP 
medications were taken: haloperidol (30 cases), zuclopenthixol (n=29), cloza-
pine (n=24), chlorprothixene (n=17), risperidone (n=13), olanzapine (n=11), 
aripiprazole (n=6), sertindole (n=6), quetiapine (n=5), sulpiride (n=5), perphe-
nazine (n=3), melperone (n=2), chlorpromazine (n=2) and flupenthixol (n=1). 
Patients with SCH suffered neither from comorbid psychiatric disorder nor from 
somatic disease caused primarily by inflammation imbalance. 
CSs were recruited by advertisement among hospital staff and the general 
public of the same geographical area. Inclusion criteria for the control group 
were the absence of a personal history of diabetes mellitus, cardiac or inflam-
matory illness, or severe mental disorder (including psychotic, bipolar and 
major depressive disorder). Exclusion criteria for the control group also in-




4.2.1. Procedures and laboratory measurements 
All venous blood samples were taken from the antecubital vein after subjects 
had fasted overnight for a minimum of 12 hours, between the hours of 9am and 
10am. Blood (5 ml) was sampled using anticoagulant-free tubes and kept for 1 h 
at 4 °C (for platelet activation) before the serum was isolated. Blood samples 
were centrifuged at 2000 rpm for 15 min at 4 °C, and then the serums from FEP 
patients and their CSs were stored at -20 °C and serums from chronic patients 
and their CSs were kept at -80 °C until testing.   
 
 
4.2.2. Biochemical analyses, and measurements of 
inflammatory, metabolic protein biomarkers, and ACs 
4.2.2.1. Biochemical measurements  
Biochemical analyses, including TGs, LDL-c, HDL-c, glycated hemoglobin 
(HbA1c) and C-reactive protein (CRP) were determined by standard clinical 
laboratory methods using certified assays performed at the Tartu University 
Hospital’s Clinical Laboratory, Estonia. 
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4.2.2.2. Measurement of inflammatory biomarkers  
High-sensitivity biochip array technology (Randox Biochip, RANDOX Labora-
tories Ltd., Crumlin, UK) was used for simultaneous quantitative detection of 
multiple analyses. The core technology of the Randox Biochip is a solid-state 
device that contains an array of discrete test regions of immobilized antibodies 
specific to different cytokines and growth factors. A sandwiched chemilumi-
nescent immunoassay was employed (according to the manufacturer’s protocol) 
on the cytokine array to measure the serum concentration of cytokines (TNF-α, 
IFN-γ, PAI-1, IL-1α, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, and MCP-1) and 
growth factors (VEGF and EGF). The results were expressed as picograms per 
milliliter. The reproducibility of the assay for individual cytokines was deter-
mined using the quality controls provided with the kit.  
 
 
4.2.2.3. Measurement of metabolic protein biomarkers  
The following metabolic biomarkers: C-peptide, insulin, leptin, resistin, and 
ferritin, were measured according to biochip array technology (Randox Biochip, 
RANDOX Laboratories Ltd, Crumlin, U.K., Metabolic Syndrome Array I for 
Evidence Investigator™).  
Intra-assay and inter-assay precisions for inflammatory and protein meta-
bolic biomarkes are given in Supplementary Table A-5, Table A-6, and Table 
A-8. Supporting information, units and sensitivity are provided in Supple-
mentary Table A-7, and Table A-9.   
The serum concentrations of adiponectin (ng/ml) were analysed by a quanti-
tative sandwich enzyme immunoassay technique, using a commercially avail-
able kit (R&D Systems, Minneapolis, MN, USA). Intra-assay and inter-assay 
presicions are given in Supplementary Table A-10.  
 
 
4.2.2.4. Measurement of ACs 
The serum levels of ACs were determined with the AbsoluteIDQTM p180 kit 
(BIOCRATES Life Sciences AG, Innsbruck, Austria) using the flow injection 
analysis tandem mass spectrometry ([FIA]−MS/MS) as well as high-perfor-
mance liquid chromatography ([HPLC]−MS/MS) technique. All measurements 
were performed as described in the manufacturer’s manual UM-P180. Identi-
fication and quantification of the metabolites were achieved using multiple re-
actions monitoring along with internal standards. From all statistically impor-
tant changes of ACs in our study, in the discussion, we only used values that 
were at least 2.3 times higher than the level of detection (LOD) given in the 
manual of the Biocrates AbsoluteIDQ p180. The calculation of metabolite con-
centrations was automatically performed by MetIDQ software (BIOCRATES 
Life Sciences AG). To ensure data quality, they were checked based on the 
LOD. Average values of all measured ACs are presented in Supplementary 
Table A-11. 
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4.3. Statistical analysis 
4.3.1. Demographic and clinical variables 
Group differences regarding demographic characteristics were analyzed using a 
t-test or Chi-square test (Paper I, II, and III). An alpha of 0.05 was used as the 
cutoff for significance.  
 
 
4.3.2. Inflammatory, metabolic protein biomarkers and  
ACs variables  
The application of Shapiro-Wilk tests indicated that some of the inflammatory, 
metabolic and growth factor marker values were not normally distributed (p < 
0.05). A Mann-Whitney U-test was applied to compare these parameters of the 
SCH patients and CSs (Paper III), and the AP-naïve FEP patients and CSs 
(Paper I and II). Wilcoxon Matched Pairs Test was used to compare the FEP 
patients’ pre- and post-treatment conditions. Differences between FEP patients 
and CSs (based on the Mann-Whitney U-test), and differences between the pre- 
and post-treatment values within the patient's group (based on the Wilcoxon 
Matched Pairs Test) were considered to be significant at p < 0.005 (Paper I) or p 
< 0.001 (Paper II). Additionally, effect sizes (eta-squared, ƞ2) were computed 
and interpreted as small, medium and large, with corresponding ƞ2 ranging from 
0.01 to 0.05, from 0.06 to 0.13 and ≥ 0.14, respectively (Cohen, 1988) (Paper I 
and II). Categorical (disease, gender, smoking status) and continuous (age) 
covariates were used in a general linear model (GLM) to compare biomarker 
levels (dependent variables) between groups (Paper I and II). To achieve the 
best fit of the model, the least significant variable was removed from the model 
until all variables had p-values less than 0.05. F-tests were used to further 
compare the approaches of linear models and to analyze the significant (disease 
or treatment) main effects in the final models. Furthermore, partial eta-squared 
values were established for the final models (Paper I and II). Because GLM 
analyses required normally distributed data, biomarkers' values were log10-
transformed to approximate normality. To establish the treatment main effect 
(i.e., difference between pre- and post-treatment measurement occasion) on 
BMI and serum biomarkers levels (dependent variables), within-subjects’ ana-
lysis (GLM repeated measures, adjusted for gender and smoking status) were 
utilized.  
Also, GLM analysis was utilized to examine the associations between the 
ratio of TGs to HDL-c (TGs/HDL-c) and biomarkers as well as LDL-c, HbA1c 
serum levels and their main effects in patients (Paper III). 
The statistical analyses were performed using Statistica software (StatSoft Inc., 




5.1. Inflammatory, metabolic and  
metabolomic alterations in FEP (Paper I, II) 
5.1.1. General description of the study groups 
There were no significant differences between FEP patients at admission and 
CSs in terms of age, gender or BMI values (Table 1). The 7-month AP treat-
ment caused a significant change in BMI, and mean BMI gain at 7-month 
follow-up was 3.0 (±2.2) kg/m2. During the 7-month treatment, psychopatho-
logy total score decreased significantly (Z=5.2, p <1E-06). Also, the difference 




Table 1. Demographic variables of FEP patients (n=38) and CSs (n=37) and clinical 









CSs Comparisons p-values 
Age, years  
(mean ± s.d.) 
25.4 ± 5.5 - 24.8 ± 5.3  t =0.49 p = 0.62 
Gender  
(male / female) 21/17 - 16/21 Χ
2
(1)
 = 1.08, p = 0.30 
BMI  
(mean ± s.d.) 22.6 ± 2.9
a 25.6 ± 4.0b 23.0 ± 3.0 t(73) = -0.69,  p = 0.49
a 
t(35) = -8.07, p <1E-06b 
Smoking status    
(male / female) 8 (8/0) 8 (8/0) 7 (3/4) Χ
2
(1)
 = 0.05, p = 0.82a 
CPZ equivalents 




58.9 ± 11.5 36.0 ± 8.3 - Z = 5.23, p <1E-06 
 
a Comparison between FEP patients and CSs;  
b Comparison between FEP patients at baseline and after 7-month AP treatment. 
AP ‒ antipsychotic; BMI – body mass index; CPZ – chlorpromazine; FEP ‒ first-






5.1.2. Differences in the level of biomarkers between 
 AP-naïve FEP patients and CSs 
Regarding measured growth factors as well as inflammatory and metabolic 
markers, a significant elevation of EGF, IL-4, IL-6, ferritin, resistin, and PAI-1 
levels, and decrease in leptin, and IL-1β levels emerged when AP-naïve FEP 
patients were compared to CSs (Table 2). According to our sample, elevated 
serum levels of IL-4, IL-6, PAI-1, ferritin and resistin, and decreased levels of 
IL-1β and leptin were associated with a moderate effect size and EGF level was 
associated with a large effect size of the disease impact. 
As for the measured carnitine, 39 ACs, and hexoses twenty-three ACs and 
hexoses exhibited shifts in FEP patients compared to CSs (descriptive informa-
tion about all measured biomarkers is provided in the Appendix Table A-1). 
Significant differences in seven increased ACs levels (C14:1, C16, C16:1, 
C16:1-OH, C18:1, C18:2, C6[C4:1-DC]), and one decreased AC (C3) level 
demonstrated large effect sizes. Additionally, elevated levels of C3-DC(C4-
OH), C18, C14:2, and decreased levels of C5, C9 with effect size of 0.10 ̶ 0.14 
occurred when AP-naïve FEP patients were compared with CSs (Table 2). 
    
Table 2. Comparisons of inflammatory and metabolic biomarkers levels (pg/mL) 














Ƞ2 Median        
(min–max) 
Median        
(min–max) 
Inflammatory biomarkers and growth factor 
 IL (Interleukin)-1βa 1.29 (0.44 – 3.44) 
1.91 
(0.45 – 4.47) -3.02 0.003 0.12 
IL-4a 1.70 (1.02 – 3.75) 
1.30 
(0.96 – 2.84) 3.18 0.001 0.13 
 IL-6a 1.07 (0.33 – 5.03) 
0.60 
(0.13 – 1.93) 3.17 0.002 0.13 
 PAI  
 (Plasminogen activator  
 inhibitor)-1b 
25.68 
(8.92 – 48.58) 
21.35 
(7.57 – 49.88) 2.75 0.006 0.10 
 Ferritinb 56.0 (4.26 – 238.7) 
22.1 
(1.22 – 184.7) 2.86 0.004 0.11 
 EGF  
  (Epidermal growth factor)a 
17.55 
(2.20 – 51.83) 
2.05 
(0.66 – 7.74) 6.67 <1E-06 0.59 
Metabolic protein biomarkersb 
  Leptin 0.85 (0 – 2.22) 
1.41 
(0.38 – 6.69) -2.73 0.006 0.11 
  Resistin 2.96 (1.69 – 8.58) 
2.66 














Ƞ2 Median        
(min–max) 






(0.03 – 0.15) 
0.04 




(0.01 – 0.07) 
0.02 
(0.01 – 0.05) -3.10 0.002 0.13 
C16 (Hexadecanoylcarnitine) 0.12 (0.06 – 0.20) 
0.09  




(0.02 – 0.06) 
0.02 




(0.01 – 0.02) 
0.01  
(0.01 – 0.02) -3.42 0.0006 0.16 
C18 (Octadecanoylcarnitine) 0.05 (0.03 – 0.09) 
0.04 




(0.05 – 0.23) 
0.09  




(0.02 – 0.07) 
0.03  
(0.01 – 0.05) -3.68 0.0002 0.18 
C3 (Propionyl-carnitine) 0.23 (0.14 – 0.49) 
0.31  





(0.03 – 0.25) 
0.04 





(0.02 – 0.05) 
0.03 
(0.02 – 0.04) -3.43 0.0006 0.16 
C5 (Valerylcarnitine) 0.14 (0.10 – 0.31) 
0.17  
(0.10 – 0.29) 2.73 0.006 0.10 
C9 (Nonaylcarnitine) 0.05  (0.03 – 0.08) 
0.06 
(0.03 – 0.12) 2.88 0.004 0.11 
 
Z-adjusted values according to Mann-Whitney U-test (FEPb compared to CSs).  
The table contains between-groups difference data with the effect size ≥ 0.10. 
a High-sensitive biochip array technology was used to measure levels of cytokines and 
growth factors. 
b Metabolic biochip array technology was used to measure metabolic and additional 
inflammatory markers. 
c  Serum level of ACs was determined using the AbsoluteIDQ™ p180 kit. 





In conclusion, AP-naïve FEP patients had a significant profile change of the 
serum levels of inflammatory, metabolic protein biomarkers, and ACs com-
pared with CSs.  
Thereafter a multivariate GLM analysis was performed to confirm a signi-
ficant main effect of the disease on the measured putative biomarker levels. The 
final regression model was built from a set of candidate predictors, by removing 
predictors on p-values (p > 0.05), in a stepwise manner. The proposed model 
appeared to fit well in estimating the difference between AP-naïve FEP patients 
and CSs as measured by 32 biomarkers (F(32,34) = 6.22, p < 1E-06, partial ƞ2 = 
0.85) (Table 3).  
 
Table 3. Acylcarnitines, growth factors, metabolic and inflammatory biomarker 
serum levels in FEP patients before treatment with APs compared to CSc.   
 
Biomarkers β β (95 % CI) t-value p-value 
Inflammatory markers and growth factor 
IL (Interleukin)-4a 0.38 0.15, 0.61 3.36 0.001 
IL-6a 0.40 0.18, 0.63 3.53 0.0008 
IL-1βa -0.29 -0.52, -0.07 -2.60 0.01 
EGF (Epidermal growth factor)a 0.77 0.61, 0.93 9.75 <1E-06 
Ferritinb 0.29 0.11, 0.48 3.14 0.003 
PAI (Plasminogen activator inhibiitor)-1b 0.28 0.06, 0.49 2.53 0.01 
Metabolic protein biomarkersb 
Resistin 0.30 0.07, 0.54 2.55 0.01 
Leptin -0.29 -0.51, -0.07 -2.65 0.01 
Acylcarnitinesc  
C10 (Decanoylcarnitine) 0.34 0.11, 0.57 2.96 0.004 
C12 (Dodecanoylcarnitine) 0.33 0.09, 0.56 2.79 0.007 
C12:1 (Dodecenoylcarnitine) 0.30 0.07, 0.53 2.60 0.01 
C14 (Tetradecanoylcarnitine) 0.34 0.11, 0.57 2.99 0.004 
C14:1 (Tetradecenoylcarnitine) 0.47 0.25, 0.68 4.37 0.00005 
C14:1-OH 
(Hydroxytetradecenoylcarnitine) 0.34 0.10, 0.57 2.87 0.006 
C14:2 (Tetradecadienylcarnitine) 0.44 0.22, 0.66 3.95 0.0002 
C16 (Hexadecanoylcarnitine) 0.49 0.28, 0.71 4.65 0.00002 
C16:1 (Hexadecenoylcarnitine) 0.56 0.36, 0.75 5.73 <1E-06 
C16:1-OH 
(Hydroxyhexadecenoylcarnitine) 0.46 0.24, 0.67 4.27 0.00007 
C18 (Octadecanoylcarnitine) 0.34 0.11, 0.57 2.90 0.005 
C18:1 (Octadecenoylcarnitine) 0.56 0.36, 0.76 5.56 1E-06 
C18:2 (Octadecadienylcarnitine) 0.44 0.23, 0.66 4.08 0.0001 
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Biomarkers β β (95 % CI) t-value p-value 
C2 (Acetylcarnitine) 0.25 0.03, 0.47 2.23 0.03 
C3 (Propionylcarnitine) -0.43 -0.64, -0.21 -4.00 0.0002 
C3-DC(C4-OH) (Malonylcarnitine 
(Hydroxybutyrylcarnitine)) 0.36 0.14, 0.59 3.20 0.002 
C4 (Butyrylcarnitine) -0.31 -0.53, -0.09 -2.75 0.008 
C6(C4:1-DC) (Hexanoylcarnitine  
(Fumarylcarnitine)) 0.45 0.23, 0.67 4.02 0.0002 
C5 (Valerylcarnitine) -0.25 -0.48, -0.02 -2.18 0.03 
C5-DC(C6-OH) (Glutarylcarnitine  
(Hydroxyhexanoylcarnitine)) 0.23 0.003, 0.46 2.02 0.047 
C7-DC (Pimelylcarnitine) 0.26 0.02, 0.49 2.18 0.03 
C8 (Octanoylcarnitine) 0.25 0.01, 0.49 2.10 0.04 
C9 (Nonaylcarnitine) -0.35 -0.58, -0.12 -3.00 0.004 
  Hexoses 0.27 0.05, 0.50 2.41 0.02 
 
β – regression coefficients, CI – confidence intervals,  
p-values (derived from GLM analysis) – significance values of log10-transformed 
biomarkers serum levels, adjusted for gender, age and smoking status. 
a  High-sensitive biochip array technology was used to measure levels of cytokines. 
b Metabolic biochip array technology was used to measure metabolic and additional 
inflammatory markers. 
c  Serum level of ACs and hexose were determined with the AbsoluteIDQ™ p180 kit. 
APs ‒ antipsychotics; CSs ‒ control subjects; FEP ‒ first-episode psychosis. 
 
 
Most notable elevations emerged in the levels of EGF, C16:1, C18:1, C16, 
C14:1, C16:1-OH, C18:2, C14:2, C6(C4:1-DC), and IL-6 in the patient group. 
In addition, the level of C3 was significantly reduced in the FEP patients’ group 
as compared with CSs. Thus, our results demonstrate that there is a disease-
dependent interaction between ACs, hexoses, metabolic protein biomarkers and 
inflammatory markers.     
5.1.3. Effects of AP treatment on BMI, growth factors, 
inflammatory and metabolic protein biomarkers, and  
ACs profiles 
Several measured biomarker levels were significantly changed after the 7-
month AP in FEP patients (Table 4, Appendix Table A-2). The strongest 
decline was observed for EGF, followed by IL-2, ferritin, and IL-6. By contrast, 
the levels of C-peptide and leptin had significantly increased after treatment. 
The number of patients displaying the level of C-peptide higher than 2 pg/ml 
before treatment was 5 out of 35, whereas after the 7-month AP treatment the 
respective number of such patients increased to 17. Moreover, continuous  
37 
7-month AP treatment resulted in a significant shift in favor of the C-peptide 
compared to insulin (Z = 3.29, p < 0.001), and showed a significant shift (Z = 
3.91, p = 0.00009) in favor of leptin compared to adiponectin. Furthermore, 
significant trends emerged for the 17 measured ACs (Table 4, Appendix Table 
A-2). However, four of them (C16, C18:1, C18:2, C3) were associated with a 
large effect size of the treatment impact.   
 
 
Table 4. Comparisons of growth factors, inflammatory and metabolic protein bio-
markers as well as acylcarnitines levels between FEP patients before and after 7-month 






after AP  











Inflammatory biomarkers and growth factor 
 IL (Interleukin)-1αb 0.30 (0 – 1.78) 
0.24 
(0 – 1.77) 2.47 0.01 0.11 
 IL-2a 3.05 (1.18 – 3.99) 
2.06 
(1.14 – 3.34) 4.78 2E-06 0.32 
 IL-4a 1.70 (1.02 – 3.75) 
1.35 
(0.92 – 4.32) 2.88 0.004 0.12 
 IL-6a 1.10 (0.34 – 5.03) 
0.60 
(0.19 – 2.27) 3.34 0.0008 0.16 
 INF (Interferon)-γa 0.34 (0.20 – 0.77) 
0.21 
(0.17 – 0.69) 3.21 0.001 0.16 
 Ferritinb 56.0 (4.26 – 238.7) 
30.9 
(4.75 – 150.0) 4.19 0.00003 0.25 
 EGF  
 (Epidermal growth factor)a 
17.55 
(2.20 – 51.83) 
1.68 
(0.49 – 7.74) 5.16 <1E-06 0.38 
Metabolic protein biomarkersb 
 C-peptide 0.80 (0.12 – 4.48) 
1.90 
(0.28 – 7.71) 3.10 0.002 0.14 
 Leptin 0.85 (0 – 2.22) 
1.21 
(0 – 9.29) 3.38 0.0007 0.16 
 Adiponectin 7335 (2093 – 2334) 
5591 
(1084 –10223) 2.43 0.02 0.12 
 Resistin 2.96 (1.69 – 8.58) 
2.80 








after AP  












 C14:2 (Tetradecadienyl- 
 carnitine) 
0.02 
(0.01 – 0.07) 
0.02 
(0.01 – 0.04) 2.75 0.006 0.11 
 C16   
 (Hexadecanoylcarnitine) 
0.12 
(0.06 – 0.20) 
0.08 
(0.04 – 0.15) 3.40 0.0007 0.16 
 C16:1 (Hexadecenoyl- 
 carnitine) 
0.03 
(0.02 – 0.06) 
0.02 
(0.01 – 0.05) 3.05 0.002 0.13 
 C16:1-OH (Hydroxyhexa- 
 decenoylcarnitine) 
0.01 
(0.01 – 0.02) 
0.01 
(0.01 – 0.02) 2.62 0.009 0.10 
 C18  
 (Octadecanoylcarnitine) 
0.05 
(0.03 – 0.09) 
0.04 
(0.02 – 0.06) 2.70 0.007 0.10 
 C18:1    
 (Octadecenoylcarnitine) 
0.13 
(0.05 – 0.23) 
0.08 
(0.04 – 0.17) 4.13 0.00004 0.24 
 C18:2 (Octadecadienyl-  
 carnitine) 
0.04 
(0.02 – 0.07) 
0.03 
(0.02 – 0.05) 3.86 0.0001 0.21 
 C3 (Propionylcarnitine) 0.23 (0.14 – 0.49) 
0.30 
(0.14 – 0.62) 3.22 0.001 0.15 
 C3-DC(C4-OH) (Malonyl- 
 carnitine (Hydroxy- 
 butyrylcarnitine)) 
0.05 
(0.03 – 0.25) 
0.04 
(0.03 – 0.07) 2.69 0.007 0.10 
 
Z-values according to Wilcoxon Matched Pairs Test (FEP patients, pre- and post-
treatment occasions).  
The table contains between groups difference data with effect size ≥ 0.10. 
a High-sensitive biochip array technology was used to measure levels of cytokines. 
b Metabolic biochip array technology was used to measure metabolic protein and 
additional inflammatory markers. 
c Serum level of ACs was determined with the AbsoluteIDQ™ p180 kit. 
AP ‒ antipsychotic; CSs ‒ control subjects; FEP ‒ first-episode psychosis. 
 
 
To provide a more comprehensive framework for the essence of inflammatory 
as well as metabolic protein biomarkers and ACs profile differences within the 
groups, we expanded our data analysis. Repeated measure GLM analysis re-
vealed that statistically significant main effects of the seven-month AP treat-
ment included 13 ACs, IL-2, IL-4, INF-γ, EGF, C-peptide, leptin, and BMI 
(Table 5). During the treatment, the most prominent changes emerged for the 
levels of EGF, IL-2 and C18:1. The effect size (partial eta-squared) of the final 
model was 0.83 (F(20.44) = 10.49, p < 1E-06).  
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Table 5. Effects of 7-month treatment with APs on biomarker levels in FEP patients.  
Biomarkers β β (95 % CI) t-value p-value 
Inflammatory biomarkers and growth factor 
  IL (Interleukin)-2a 0.68 0.41, 0.94 5.14 3E-06 
  IL-4a 0.44 0.13, 0.74 2.89 0.005 
  INF (Interferon)-γa 0.35 0.04, 0.66 2.23 0.03 
  EGF (Epidermal growth factor)a 0.75 0.55, 0.96 7.37 <1E-06 
Metabolic protein biomarkersb 
  C-peptide -0.31 -0.63, 0.00 -2.01 0.048 
  Leptin -0.34 -0.62, -0.05 -2.36 0.02 
Body mass index (BMI) -0.52 -0.83, -0.21 -3.36 0.001 
Acylcarnitinesc 
C14 (Tetradecanoylcarnitine) 0.39 0.08, 0.71 2.51 0.01 
C14:1 (Tetradecanoylcarnitine) 0.42 0.12, 0.72 2.81 0.007 
C14:1-OH 
(Hydroxytetradecenoylcarnitine) 0.38 0.06, 0.70 2.38 0.02 
C14:2 (Tetradecadienylcarnitine) 0.45 0.15, 0.75 2.98 0.004 
C16 (Hexadecanoylcarnitine) 0.47 0.18, 0.77 3.19 0.002 
C16:1 (Hexadecenoylcarnitine) 0.46 0.18, 0.74 3.25 0.002 
C16:1-OH 
(Hydroxyhexadecenoylcarnitine) 0.42 0.11, 0.72 2.73 0.008 
C18 (Octadecanoylcarnitine) 0.41 0.08, 0.73 2.52 0.01 
C18:1 (Octadecenoylcarnitine) 0.54 0.27, 0.81 3.98 0.0002 
C18:1-OH (Hydroxyoctadecenoylcarnitine) 0.36 0.04, 0.68 2.26 0.03 
C18:2 (Octadecadienylcarnitine) 0.45 0.16, 0.74 3.13 0.003 
C3 (Propionylcarnitine) -0.39 -0.70, -0.07 -2.44 0.02 
C3-DC(C4-OH) (Malonylcarnitine 
(Hydroxybutyryl-carnitine)) 0.41 0.12, 0.70 2.81 0.007 
 
β – regression coefficients, CI – confidence interval, 
p-values (derived from GLM repeated measure) – significance values of log10-trans-
formed biomarkers serum levels in patients’ group before treatment compared to bio-
markers values measured after the 7-month treatment with APs.  
a High-sensitive biochip array technology was used to measure levels of cytokines. 
b Metabolic biochip array technology was used to measure metabolic markers. 
c Serum level of ACs was determined with the AbsoluteIDQ™ p180 kit. 
AP ‒ antipsychotic; CSs ‒ control subjects; FEP ‒ first-episode psychosis. 
 
 
In conclusion, during the 7-month AP-treatment, EGF serum level demonstrated 
the strongest decline, followed by IL-2, C18:1, C16, C16:1, and C18:2. 
Simultaneously, an increased level of C-peptide and leptin and a decreased level 
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of adiponectin were found among the metabolic protein markers. In addition, 
continuous AP-treatment was associated with significantly increased BMI in the 
FEP patients’ group.  
 
 
5.1.4. Comparisons of levels of growth factors, inflammatory and 
metabolic protein biomarkers, and ACs profiles between FEP 
patients after 7-month AP treatment and CSs 
In the next step, the inflammatory and metabolic status of treated FEP patients 
was compared with CSs. Importantly, significant elevation emerged in the 
levels of several cytokines: IL-1α, IL-1β, IL-2, INF-γ (Table 6), and C-peptide 
(Appendix Table A-3) when treated FEP patients were compared to CSs. By 
contrast, previously demonstrated elevated levels of EGF, ferritin, IL-6, IL-4, 
PAI-1, and resistin, as well as the diminished level of leptin (Table 2, Appendix 
Table A-2), had returned to the level of CSs (Appendix Table A-3). No 
differences in ACs levels were detected between the post-treatment status of 
FEP patients and CSs (Appendix Table A-3).  
 
 
Table 6. Comparisons of inflammatory biomarkers levels (pg/mL) between FEP 












Ƞ2 Median        
(min–max) 
Median        
(min–max) 
Inflammatory biomarkers  
 IL (Interleukin)-1αb 0.24 (0.00 – 1.77) 
0.32 
(0.20 – 1.67) -2.89 0.004 0.12 
 IL-1βa 1.21 (0.40 – 3.39) 
1.91 
(0.45 – 4.47) -3.35 0.0008 0.16 
 IL-2a 2.06 (1.14 – 3.34) 
2.81 
(1.34 – 4.49) -4.55 5E-06 0.28 
  INF (Interferon)-γa 0.21 (0.17 – 0.69) 
1.30 
(1.02 – 3.75) -3.07 0.002 0.13 
 
Z-adjusted values according to Mann-Whitney U-test (FEP patients after 7-month 
treatment compared to CSs).  
The table contains between groups difference data with effect size ≥ 0.10. 
a High-sensitive biochip array technology was used to measure levels of cytokines. 
b Metabolic biochip array technology was used to measure the level of cytokine. 
AP ‒ antipsychotic; CSs ‒ control subjects; FEP ‒ first-episode psychosis. 
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In conclusion, comparing CSs to patients with FEP during the 7-month AP 
treatment, the levels of certain cytokines (IL-1α, IL-1β, IL-2, INF-γ) and meta-
bolic proteins (C-peptide and leptin levels) had an upward trend, and the ACs 
had returned to CSs level.  
5.2. The difference in the profiles of inflammatory and 
metabolic protein markers between patients with the 
chronic stage of SCH spectrum disorders and CSs (Paper III) 
5.2.1. General description of the study groups  
There were no statistically significant differences between the two groups 
(patients with SCH spectrum disorders and CSs) in terms of age (t(251) = 1.56, 
ns), and gender (χ2(1) = 0.24, ns), as seen in Table 7. Patients had a significantly 
higher (p = 0.007) BMI compared to CSs. Among the patients' group, the mean 
disease duration was 19.9 (±9.8) years and the value of the mean PANSS 
general psychopathology symptom score was 76.2 (±29.1). 
 
 






Age, years (mean ± s.d.) 53.1 ± 10.9 51.3 ± 7.57 t = 1.56, p = 0.12 
Gender (male / female) 45/60 68/80 Χ2(1) = 0.24, p = 0.63 
BMI (mean ± s.d.) 27.9 ± 6.4 24.5 ± 2.9 t(124) = 2.76,  p = 0.007 
PANSS (total symptom score) 76.2 ± 29.1 - - 
 
BMI – body mass index; CSs ‒ control subjects; PANSS – Positive and Negative 
Syndrome Scale.  
 
 
5.2.2. Biochemical measurements  
for clinical routine blood tests  
While biochemical blood test data were available only for patients, we used the 
endemic reference values (ERV) to assess the prevalence of cardio-metabolic 
risk factors in the patients' group (Table 8). The CRP, TGs, and LDL-c mean 
levels were somewhat higher in patients compared to the ERV. The level of 
TGs of 52 patients fell outside the ERV. The same trend emerged for 48 and 46 
patients when ratios of TGs/HDL-c and LDL-c/HDL-c values were compared to 
ERV. Calculation of the ratio for TGs/HDL-c and LDL/HDL-c revealed the 
elevation in patients of both genders. The level of HbA1c for the whole patient 
group was close to the upper threshold of the ERV. In more detail, our results 
demonstrated that a relatively high number of patients were in a pre-diabetic/ 
diabetic state. The number of patients in a pre-diabetic state (HbA1c over 6.0%) 
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was 28 (26.7%) and the number of patients exceeding the threshold for diabetes 
(HbA1c over 6.5%) was 6 (5.7%). Altogether, 32.4% of the SCH patients were 
in a pre-diabetic/diabetic state and significantly higher HbA1c values emerged 
among the female patients (Z = 2.15, p = 0.03). According to the clinical 
records, 11 patients (10.5%) had already received a diagnosis of T2DM. Nine of 
the confirmed diabetic patients were under treatment with anti-diabetic drugs 
(one of them needed insulin). 
 
 
Table 8. Biochemical parameters of patients with SCH spectrum disorders compared to 





Mean ± standard error of 
the mean and range in 
parentheses 
Number (%) of patients 
whose blood biochemical 
parameters were  
out of limit of the ERV 
CRP (< 5 mg/L) 5.20 ± 0.86 (0.90 – 66) 30 (28.6%) 
TGs (< 1.7 mmol/L) 2.00 ± 0.11 (0.38 – 7.16)  52 (53.3%) 
HDL-c 
  (male >1.0 mmol/L,  
  female >1.2 mmol/L) 
1.35 ± 0.04 (0.55 – 3.09) Male: 9 (20.0%) Female: 28 (43.3%) 
TGs/HDL-c 
  (male < 1.7, female < 1.4) 1.74 ± 0.14 (0.20 – 11.4) 
Male: 20 (44.4%) 
Female: 28 (46.7%) 
LDL-c (< 3.0 mmol/L) 3.84 ± 0.11 (1.65 – 7.40) 77 (73.3%) 
LDL-c/HDL-c  
  (male < 3.0, female < 2.5) 3.13 ± 0.13 (0.74 – 6.57) 
Male: 19 (42.2%) 
Female: 27 (45.0%) 
HbA1c (< 6.0 %) 5.90 ± 0.10 (4.83 – 13.72) 34 (32.4%) 
 
CRP ‒ C-reactive protein; HbA1c ‒ glycated hemoglobin; HDL-c ‒ high-density lipo-
protein cholesterol; TGs ‒ triglycerides; LDL-c ‒ low-density lipoprotein cholesterol; 
SCH ‒ schizophrenia. 
 
Ratios of TGs/HDL-c and LDL/HDL-c were elevated in patients of both 
genders and the level of HbA1c for the whole patient group was close to the 
upper threshold of the ERV.   
5.2.3. Biomarker level differences among patients with  
SCH spectrum disorders and CSs  
The differences in the levels of cytokines and growth factors varied between pa-
tients and CSs (Table 9, Appendix Table A-4). The most prominent elevations 
(effect size ƞ2 ≥ 0.13) were detected in the levels of widely recognised pro-
inflammatory markers: IL-2, IL-6, IL-8, IFN-γ, MCP-1 as well as the anti-
inflammatory marker IL-10 in patients’ group compared to CSs. Similarly, the 
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ratios of INF-γ/IL-4 and INF-γ/IL-10 (i.e. these ratios were used to evaluate the 
balance between pro-inflammatory and anti-inflammatory cytokines) were 
significantly higher in patients compared to CSs. Contrary, the ratio of IL-
2/INF-γ (a common feature of autoimmune disorder) was significantly lower in 
the patients’ group. It is also worth emphasizing that the values of some well-
known pro-inflammatory markers (IL-1α, IL-1β and TNF-α) were not signi-
ficantly different between the two study samples. 
 
 
Table 9. Inflammatory markers values (pg/mL) of patients with SCH spectrum dis-
orders compared to CSs.  
 






Ƞ2 Median (min–max) 
Pro-inflammatory cytokinesa 
IL (Interleukin)-2  2.18 (0.80 – 8.10) 1.21 (0.47 – 2.97) 8.78 <1E-06 0.31 
IL-6  1.80 (0.38 – 28.20) 0.89 (0.33 – 2.29) 8.01 <1E-06 0.26 




244.8 (42.75 – 741.9) 165.3 (26.90 – 345.2) 6.98 <1E-06 
 
0.19 
IFN (Interferon)-γ  4.12 (0.41 – 38.87) 1.23 (0.16 – 4.10) 9.93 <1E-06 0.40 
Anti-inflammatory cytokinesa 
IL-10 0.77 (0.21 – 7.46)  0.55 (0.20 – 1.32)  6.27 <1E-06 0.16 
Ratio of biomarkers 
INF-γ/IL-4  3.09 (0.38 – 21.24) 0.75 (0.12 – 4.82) 9.63 <1E-06 0.37 
INF-γ/IL-10 4.35 (0.34 – 56.23) 2.00 (0.15 – 12.71) 6.26 <1E-06 0.16 
IL-2/INF-γ 0.60 (0.09 – 6.24) 1.14 (0.24 – 7.09) -5.61 <1E-06 0.13  
Z-adjusted values according to Mann-Whitney U-test.  
The table contains between groups difference data with effect size ≥ 0.10. 
a High-sensitive biochip array technology was used to measure levels of cytokines. 
CSs ‒ control subjects; SCH ‒ schizophrenia. 
 
 
The logistic regression analysis was performed in order to confirm the results of 
non-parametric difference test on the two groups. Age, gender, and BMI were 
used as covariates in the models. First, we conducted a series of univariate 
logistic regression analyses to select candidate variables for the final model. For 
that, we used the p-value cut-off point of 0.10. Based on to the results of the 
univariate logistic regression analyses, we found that IL-2 (W = 53.63, p < 1E-
06), INF-γ (W = 43.99, p < 1E-06), IL-6 (W = 42.88, p < 1E-06), MCP-1 (W = 
39.33, p < 1E-06), IL-8 (W = 33.4, p < 1E-06), IL-10 (W = 25.61, p < 1E-06), 
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VEGF (W = 11.96, p = 0.0006), EGF (W = 10.25, p = 0.001), and TNF-α (W = 
3.09, p = 0.08) showed greater Wald statistic parameters than the other variables 
(IL-1α, IL-1β, IL-4). Thereafter, a multivariate logistic regression analysis 
revealed that elevated levels of IL-2, IL-6, IL-10, and INF-γ were associated 
with the higher risk of belonging to the patient group (odds ratios (OR): 4.55, 
4.16, 10.36, 2.62, respectively) (Table 10). The high level of TNF-α was 
associated with a lower risk (OR = 0.29) of belonging to the SCH patient group. 
In contrast, IL-8, MCP-1, VEGF, EGF levels, as well as gender and age, were 
not significant predictors in the multivariate model to differentiate groups. Next, 
we demonstrated that the disease was associated with pro-inflammatory/anti-
inflammatory (INF-γ/IL-4) balance disturbances (OR = 3.68, CI 95% = 1.61 – 
8.41, p < 0.002), and this INF-γ/IL-4 imbalance was accompanied by older age 
(OR = 1.06, CI 95% = 1.01 – 1.11, p < 0.03), and higher BMI (OR = 1.24, CI 
95% = 1.08 – 1.42, p < 0.002). Ratios of INF-γ/IL-10 and IL-2/INF-γ were not 




Table 10. Multivariate logistic regression analysis of variables associated with the risk 
of belonging to the group of patients with SCH spectrum disorders. 
Variables Odds ratio 95 % CI p-value 
Pro-inflammatory cytokinesa  
IL (Interleukin)-2  4.55 2.00, 10.34 0.00003 
IL-6  4.16 1.48, 11.68 0.007 
IL-8  1.24 0.99, 1.55 ns 
MCP (Monocyte chemo-attractant protein)-1  1.00 0.99, 1.03 ns 
TNF (Tumor necrosis factor)-α 0.29 0.13, 0.63 0.002 
IFN (Interferon)-γ  2.62 1.65, 4.17 0.00005 
Anti-inflammatory cytokinesa  
IL-10  10.36 1.43, 78.82 0.02 
Growth factorsa  
   VEGF (Vascular endothelial growth factor) 1.00 0.99, 1.01 ns 
EGF (Epidermal growth factor) 1.01 0.99, 1.03 ns 
Demographic variables 
Gender 0.66 0.21, 2.10 ns 
Age 1.02 0.96, 1.08 ns 
 
CI ‒ Confidence intervals. 
a High-sensitive biochip array technology was used to measure levels of cytokines. 
SCH ‒ schizophrenia. 
 
The cytokine profile distinguished patients with SCH spectrum disorders from 
CSs. In the patient group, a statistically significant increase was found in the 
levels of pro-inflammatory markers (IL-2, IL-6, TNF-α, IFN-γ, MCP-1) and the 
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level of anti-inflammatory marker (IL-10). Besides, disturbance of the pro-/anti-
inflammatory status caused by SCH spectrum disorders and probably by its 
treatment was confirmed by the elevated value of the INF-γ/IL-4 ratio in the 
patients’ group.  
 
 
5.2.4. Relation of biomarker levels with HbA1c in patients’ group  
Thereafter, GLM analysis was performed, to establish associations between ele-
vated levels of HbA1c and inflammatory biomarkers in the patient group. 
Gender, age, and BMI were included as covariates in the model. Stepwise selec-
tion of parameters was used to achieve the best-fitted model. Outcome of the 
analysis showed that several biomarkers, INF-γ (β = 0.69, [95% CI 0.55 – 0.84], 
t = 9.46, p < 1E-06), IL-6 (β = 0.29, [95% CI 0.15 – 0.43], t = 4.21, p < 1E-06), 
MCP-1 (β = -0.22, [95% CI (-0.37) – (-0.07)], t = -2.94, p = 0.004), and IL-2  
(β = 0.18, [95% CI 0.04 – 0.32], t = 2.61, p = 0.01)) were significantly 
associated with HbA1c serum concentration in patients. The effects of age and 
BMI were not statistically significant in the final model. The explained variance 
(R2adj = 0.60) of IL-2, IL-6, INF-γ, MCP-1 on HbA1c, adjusted for gender, was 
60% (F(5) = 28.00, p < 1E-06). The higher levels of INF-γ, IL-6 and IL-2, and 
lower levels of MCP-1 were significant predictors of elevated HbA1c value in 
the patient group.  
 
 
5.2.5. Relation of metabolic and biomarker levels with  
the ratio of TGs to HDL-c in patients with  
SCH spectrum disorders  
Finally, to evaluate associations between the ratio of TGs/HDL-c (which was 
considered to indicate a risk for the development of insulin resistance and 
cardiovascular diseases) and measured serum markers, the GLM analysis was 
used. Gender, age, and BMI did not make a significant contribution to the 
regression models and were not included in the final model. The results demon-
strated that higher values of INF-γ/IL-10 ratio (β = 0.41, [95% CI 0.13 – 0.68],  
t = 2.93, p = 0.004), HbA1c (β = 0.37, [95% CI 0.12 – 0.63], t = 2.88, p = 
0.005), LDL-c (β = 0.22, [95% CI 0.03 – 0.41], t = 2.31, p = 0.02), and INF-
γ/IL-4 (β = 0.39, [95% CI 0.00 – 0.78], t = 1.99, p = 0.049), as well as a lower 
level of INF-γ (β = -0.68, [95% CI (-1.18) – (-0.18)], t = -2.68, p = 0.009) were 
the predictors of the elevated value of TGs/HDL-c ratio. The explained variance 
(R2adj = 0.19) of these biomarkers for insulin resistance and cardiovascular 
disease risk parameter (TGs/HDL-c) was 19% (F(5) = 5.51, p < 0.0001).   
Together, these results confirmed that the interplay exists between pro-/anti-
inflammatory status alteration, insulin resistance and cardiovascular disease risk 
parameter (expressed as HbA1c and as the ratio between TGs and HDL-c) in 
the patients with a chronic stage of the psychotic disorder.  
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6. DISCUSSION 
This dissertation has the following main goals: (i) to study the profiles of ACs, 
inflammatory and metabolic protein biomarkers in FEP patients before and after 
a 7-months AP-treatment and compare these to CSs, (ii) to characterize a bio-
energetic dysfunction through the a complex interplay between inflammatory 
and metabolic protein biomarkers as well as ACs profiles in patients with FEP 
before and after a 7-month AP-treatment and compare these to CS, and (iii) to 
investigate inflammatory and cardio-metabolic status alterations among patients 
with the chronic stage of the SCH spectrum disorders and compare these to 
CSs.  
The results of the research confirmed that putative biomarkers are altered in 
the serum of patients with SCH spectrum disorders at different stages of the 
disease, and suggested that peripheral immune system is over-activated and 
metabolic status is imbalanced in both the individuals undergoing their FEP and 
subjects with a chronic stage of the disease. Although the design of the study 
does not allow for establishing causation, results support the idea that low-grade 
inflammation, alterations in the lipid profile and insulin resistance play a central 
role in the pathogenesis of the SCH spectrum disorders, phenomena already 
seen in the early stage of the disease as well as during the disease progression 
and continuous AP treatment.   
 
 
6.1. Differences in the level of biomarkers between  
FEP patients and CSs 
In general, the results of this study confirmed that there are differences between 
the AP-naïve FEP patients, FEP patients after the 7-month treatment and CSs, 
in terms of certain biomarkers related to inflammatory and metabolic profiles.  
 
 
6.1.1. Putative biomarker profile differences between  
AP-naїve FEP patients and CSs 
Concerning the interplay between cytokines, growth factor, metabolic protein 
biomarkers, and ACs, we found significantly elevated levels of EGF, IL-4, IL-6, 
ferritin, PAI-1, resistin, 19 ACs and reduced levels of IL-1β, leptin, and 4 ACs 
in the group of AP-naïve patients compared to CSs.  
In comparison to CSs, the AP-naïve FEP patients showed significantly 
higher level of EGF serum concentrations. EGF exhibits neurotrophic and 
neuromodulatory effects on various types of neurons in the CNS (Yamada et al., 
1997). Preclinical studies suggest that EGF is related to the regulation of 
dopaminergic neuron activity in the CNS (Eda et al., 2013), and EGF selecti-
vely enhances the NMDA receptor-mediated increase of the intracellular 
calcium concentration in neurons (Abe & Saito, 1992). Inhibitors of EGF 
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receptors can ameliorate some of the behavioral impairments of an animal 
model for SCH (Mizuno et al., 2013). Studies have shown a link between the 
EGF receptor family or the ErbB signaling network and dopamine, GABA, and 
glutamatergic systems, and have confirmed that ErbB signaling can serve as a 
new starting point for non-dopaminergic-based drug development of SCH (Go-
lani et al., 2014; Tadmor et al., 2018). Moreover, Golani et al. (2014) demon-
strated that the alteration of ErbB signaling in the rat brain during adolescence 
results in changes to the dopaminergic system that emerges via pathological 
learning and hedonic behavior in adulthood, and suggests the possible role of 
the pathway in the development of cognitive skills and motivated behavior. It is 
speculated that increased levels of EGF in a person’s bloodstream may reflect a 
connection between psychosis and the status of the dopaminergic system. 
Furthermore, using mouse models, Wang et al. (2017) showed a link between 
epidermal growth factor receptor and regulation of oxidative stress in macro-
phages, and that the destruction of that receptor signaling pathways reduces the 
activity of inflammation. Therefore, one may suggest that increased serum 
levels of EGF in this study may reflect a connection between psychotic symp-
toms and the altered dopaminergic, GABAergic and/or glutamatergic neuro-
transmitter systems. 
The elevated level of IL-6 in AP-naïve patients has also been confirmed by 
multiple meta-analyses (Miller et al., 2011; Di Nicola et al., 2013; Upthegrove 
et al., 2014; Pillinger et al., 2019b; Fraguas et al., 2019). IL-6 is a soluble 
mediator with a pleiotropic effect on inflammation, immune response, hemato-
poiesis, and it is also involved in the regulation of metabolic, regenerative and 
nervous processes (Scheller et al., 2011). Findings suggest a potential link 
between an elevated level of IL-6 and vulnerability to OxS, which might be 
associated with GABAergic dysfunction in the brain of patients with SCH 
(Watanabe et al., 2010). Furthermore, IL-6 also has a role in minimising the 
inflammatory response by reducing the production of IL-1β and TNF-α 
(Schindler et al., 1990) and by inducing the production of anti-inflammatory 
cytokine IL-10 (Raison et al., 2018). Thus, in addition to EGF, IL-6 also 
appears to be a clear candidate biomarker of FEP, as confirmed by our study.  
In the current study, a moderate increase in IL-4 in AP-naїve FEP patients 
could probably be explained by its role in the activation of the type 2 T helper 
cells (Th2) immune response and its consequent anti-inflammatory action 
(Derecki et al., 2010; Doherty et al., 2018). It is shown in preclinical studies that 
IL-4 can decrease the integrity of the endothelium and increase the permeability 
of the BBB (Duarte-Delgado et al., 2019; Małkiewicz et al., 2019). Altered 
levels of IL-6 and IL-4 may indicate the induction of low-grade inflammation in 
AP-naїve FEP patients.  
Regarding PAI-1, increased levels in the AP-naïve FEP group compared 
with the CSs were reported by Bocchio-Chiavetto et al. (2018). For decades, 
tissue plasminogen activator was known as a protein with a main role to modu-
late coagulation through intravascular fibrin degradation. However, it is also 
synthesized and released by neurons and glial cells. Tissue plasminogen activa-
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tor is involved in synaptic plasticity, it has a role in maintaining the integrity of 
the BBB as well as to guide neurite outgrowth, cell migration, neurogenesis, 
and excitotoxic cell death (Melchor & Strikland, 2005; Benarroch, 2007). The 
PAI-1 is a serine protein inhibitor that functions as an inhibitor of tissue 
plasminogen activator (Vaughan, 2005). It has been suggested that the loss of 
that activator function may be associated with the clinical conditions related to 
SCH, such as hyperhomocysteinemia, insulin resistance, and T2DM (Hoirisch-
Clapauch & Nardi, 2013). Furthermore, in the context of AP-naїve FEP 
patients, an elevated level of PAI-1 may indicate possible sequential changes in 
the permeability of the BBB. Cesari et al. (2010) have reported that TNF-α and 
IL-6 are major contributors to the increase of PAI-1 level.  
Serum ferritin (i.e. the acute phase protein) is a well-known marker of 
inflammation, and abnormally elevated serum ferritin is a consequence of cell 
stress and damage (Kell & Pretorius, 2014; Kim et al., 2018). Ferritin is a pri-
mary marker of iron metabolism and plays an important role in maintaining iron 
metabolism homeostasis and regulating iron content in the brain (Kim et al., 
2018). Furthermore, ferritin levels were positively correlated with CNS dopa-
mine levels in Parkinson’s disease (Piao et al., 2017). Results from this study 
are consistent with a published report by Schwarz et al. (2010), describing an 
assortment of 51 analytes, among which was an elevated level of ferritin that 
could distinguish patients with SCH from CSs. Thus, the low-grade inflam-
matory state in drug-naïve FEP patients in this study is characterized by an 
increase in the level of pro-inflammatory cytokine (IL-6) and acute phase pro-
teins (i.e., ferritin and PAI-1). 
In the present study, the level of IL-1β was decreased in AP-naïve FEP 
patients when compared to CSs, and a similar trend was demonstrated by Zhu et 
al. (2018). However, these results contradicted with findings from previous 
studies (Miller et al., 2011; Di Nicola et al., 2013; Trovão et al., 2019). Such 
discrepancies may be related to different study populations (i.e. patients’ age, 
presentation of the disease or treatment duration), and the disease state.  
In this study resistin (i.e. initially described as an adipocyte-specific hor-
mone associated with obesity, insulin resistance, diabetes, and cardiometabolic 
disease (Kawabe et al., 2015)) was significantly increased in AP-naïve patients 
with FEP, while leptin (i.e., a hormone secreted by fat cells to regulate energy 
balance (Klok et al., 2007; Kelesidis et al., 2010)) was reduced. Resistin is a 
cytokine that induces low-grade inflammation by stimulating monocytes (Lee et 
al., 2014). No specific receptor has been identified for resistin, although it 
seems to share signaling pathways with other pro-inflammatory molecules 
(Bokarewa et al., 2005). The correlation between resistin and inflammatory 
markers (e.g. IL-6) is particularly noteworthy given the observation that resistin 
is produced by macrophages in response to inflammation (Filková et al., 2009; 
Schwartz & Lazar, 2011). Importantly, the resistin itself can contribute to the 
onset of inflammatory conditions by mediating enhanced activation of cytokines 
(IL-6, TNF-α) and nuclear kappa B (NF-κB) (Bokarewa et al., 2005; Stofkova, 
2010). Thus, the interaction between adipocytes and macrophages can lead to 
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hyper-resistinemia (Luo et al., 2018). An increase in the above factors can be 
considered as a possible sign of an inflammatory response during FEP.  
It has been hypothesized that leptin plays a role in SCH because of its 
relationship with weight gain and obesity (Henderson et al., 2015). However, 
studies evaluating leptin levels in patients with FEP have been inconclusive 
(Chouinard et al., 2018; Pillinger et al., 2019b; Martorell et al., 2019). Reduced 
leptin levels in this study can be viewed as a reduced nutritional status of 
patients, reflecting a slightly reduced amount of fat tissue in AP-naïve FEP 
patients. In terms of leptin, there are studies indicating its potential interaction 
with resistin (Kershaw & Flier, 2004; Rajala et al., 2004; Qi et al., 2006). What 
is more, in rodents, the effect of resistin depends on the presence or absence of 
leptin, but together they have a cross effect on the regulation of glucose energy 
and homeostasis (Qi et al., 2006).  
There were no significant differences in baseline measurements of fasting 
plasma insulin, C-peptide and adiponectin levels in AP-naïve patients with FEP 
compared to CSs, in this study. The results differed from several previous 
studies that reported higher levels of insulin and C-peptide in patients with FEP 
compared with CSs (Pillinger et al., 2017) or the absence of significant 
differences in insulin resistance in AP-naïve FEP patients compared to CSs 
(Sengupta et al., 2008). A meta-analysis conducted by Pillinger et al. (2017) 
confirmed that altered glucose homeostasis is an integral part of the disease and 
appears from the very beginning of the disease. The discrepancy between our 
results and previous studies can be partly explained by the size of the sample 
and how patients were involved in the studies. 
It is important to note that the difference in BMI values between AP-naïve 
FEP patients and CSs was not statistically significant. 
The present study also focused on the analysis of ACs profile alterations in 
the early stage of psychosis because subjects with SCH have a risk of metabolic 
abnormalities, T2DM, and multiple cardiovascular diseases (Vancampfort et al., 
2015). ACs are involved in bioenergetic pathways and provide potential bio-
marker targets for identifying early changes and onset characteristics of the bio-
energetic dysfunction. Studies suggest that SCH can be characterized by mole-
cular signatures, thus presenting opportunities to identify metabolic dysregula-
tion even before the initiation of AP treatment. ACs are the intermediate meta-
bolites produced during fatty acids oxidation (FAO). Alterations in blood and 
tissue ACs (LCACs, ≥14 chain lengths) may occur through many physiological 
and pathophysiological metabolic events in which pools of acyl-CoA) fatty acid 
metabolites are converted to ACs via conjugation to CARN by carnitine 
palmitoyltransferase 1 (CPT) or after mitochondrial translocation, CPT2 con-
verts AC to free CARN and acyl-CoA, which subsequently enters the FAO 
pathway (Knottnerus et al., 2018). Excessive accumulation of LCACs may 
occur when there is significant discordance between long-chain fatty acid 
availability, storage and oxidative utilization (McCoin et al., 2019). Evidence 
has suggested that LCACs have bioactive properties that may be integrated with 
multiple pathways involved in inflammation, cell stress, and insulin resistance 
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(McCoin et al., 2015). We found that levels of several LCACs (C14:1, C16, 
C16:1, C18:1, C18:3 among others) were increased and levels of SCACs (e.g. 
C3) were decreased when AP-naïve patients were compared to CSs. It may be 
hypothesized that the FEP correlates with a downregulated beta-oxidation of 
fatty acids, which leads predominantly to higher amounts of LCASs. What is 
more, the alterations of glucose metabolism are especially relevant in the 
context of increased risk of metabolic syndrome or T2DM in SCH. Although 
this can often be linked with APs side effects, a recent meta-analysis by Pillin-
ger et al. (2017) confirmed that altered glucose homeostasis is intrinsic to the 
disease and present from the illness onset. Evidence suggests that FEP is ac-
companied by disturbances in glucose utilization and energy production. Our 
study established an increase in hexoses levels in FEP patients compared to CSs 
which refers to possible shifts in carbohydrate metabolism. All the above-men-
tioned shifts (LCACs, hexoses) may indicate a certain mitochondrial dysfunc-
tion during FEP as mitochondria are fundamental-functional “cross-road” for 
the metabolism of lipids, glucose and amino acids. It is known that SCACs are 
tightly linked to amino acid and ketone bodies’ metabolism. Furthermore, re-
sults from this study demonstrated that there is a disease-dependent interaction 
between ACs, protein metabolic and low-grade inflammatory biomarkers in 
AP-naïve patients with FEP.  
 
 
6.1.2. Biomarker profile differences between AP-naїve FEP 
patients and FEP patients after 7-month treatment with APs  
On the background of AP treatment, the greatest decrease was found for EGF, 
followed by IL-2, ferritin, IL-6, and IL-4 among patients. According to the 
results, we may suggest that a 7-month AP treatment can reduce levels of pro-
inflammatory biomarkers and diminish low-grade inflammation in the early 
stage of the chronic psychotic disorder. Previous researches concerning the im-
pact of AP treatment on inflammatory markers, and more precisely on cytokine 
levels, have so far provided mixed findings. Some studies have found increased 
levels of inflammatory markers after continuous AP treatment, while others 
have found a reduction or no change in cytokine levels. A recent study by 
Juncal-Ruiz et al. (2019) provides additional evidence that AP treatment has an 
anti-inflammatory effect and could normalize immune balance. Moreover, 
results suggest that AP drugs may have both direct anti-inflammatory and 
indirect pro-inflammatory activity, depending on the effect on weight-gain and 
increased adiposity (Mondelli & Howes, 2014). This emphasizes the importance 
of measuring metabolic dysfunction in addition to evaluating inflammatory 
markers.   
Several metabolic biomarkers significantly changed after the 7-month AP 
treatment in FEP patients. AP treatment caused an elevation on the leptin level 
and a reduction on the resistin level. In patients with SCH spectrum disorders, 
hyperleptinemia has been described and it is correlated with AP-induced weight 
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gain and metabolic side effects of the treatment (Potvin et al., 2015), rather than 
the direct effect of atypical AP drugs on the physiology of leptin (Jin et al., 
2008; Potvin et al., 2015). Leptin level increases in conjunction with the amount 
of fat (Mantzoros et al., 2011). A paradoxical hyperleptinemic state during 
weight gain is associated with leptin resistance and indicates a loss of leptin’s 
ability to stop overeating behavior (Caro et al., 1996).  
Furthermore, treatment significantly increased the serum concentration of C-
peptide and indicated the prevalence of insulin resistance among FEP patients 
who received AP drugs compared to the metabolic state of AP- naïve FEP 
patients and CSs. According to the results of our work, the number of patients 
with C-peptide levels above 2 pg / ml increased from 5 to 17 after treatment 
with atypical APs. There has been a significant shift in favor of C-peptide in 
comparison with insulin after treatment with APs. Such a shift towards an 
increase in C-peptide level (C-peptide and insulin are released in equimolar 
amounts) is most likely due to changes in insulin sensitivity after treatment.  
The level of adiponectin in our work was significantly decreased in patients 
with FEP after 7-months of AP treatment. Similar results have been obtained by 
Barcones et al. (2018). Adiponectin is a blood protein produced by adipocytes, 
and it has anti-inflammatory effects and increases insulin sensitivity. The levels 
of the protein in the circulation decrease with an increasing BMI (Arita et al., 
1999). It is important to note that the relationship between adiponectin and 
leptin shifted in favor of leptin after 7-months of AP treatment, thus this ratio 
may be the preferable biomarker of the MetS in patients with SCH (Chen et al., 
2018). 
Additionally, the results revealed that AP drug treatment reduced the levels 
of LCACs (C16, C16:1, C18:1, C18:2, among others) and this trend was 
positively correlated with a decrease in the levels of EGF, IL-2, IL-4, and IL-6. 
Preclinical studies indicate that LCAC C18:1 (oleoyl ‐ l ‐ carnitine) inhibits the 
activity of the glycine transporter 2 carrier (GlyT2) on inhibitory nerve endings 
by increasing synaptic glycine, which reduces the excitability in nociceptive 
chains and provides analgesia in models of neuropathic and inflammatory pain 
(Carland et al., 2013). The close connection between nociceptive and inflam-
matory processes is a well-established phenomenon. At the same time, AP 
treatment was associated with an elevated level of SCAC C3 and this was in 
turn linked to elevated levels of leptin and C-peptide, as well as weight gain. 
This finding was confirmed by Cao et al. (2019) and it seems to underline the 
role of SCACs in the regulation of energy metabolism. Taking into account 
changes in markers of inflammation and metabolism during AP treatment in 
patients with FEP, it is likely that LCACs are involved in the formation and 
maintenance of inflammation, and SCACs are more involved in the develop-
ment of the metabolic syndrome.  
In this study, FEP patients received various generation AP drugs, and the 
dosages were adjusted or the drugs were replaced with another active substance 
as it was clinically necessary during the follow-up period. Therefore, it is dif-
ficult to draw any serious conclusions about the effect of specific AP drugs. 
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However, treatment improved the severity of symptoms on the PANSS psycho-
pathology scale, but this positive change was accompanied by a marked 
increase in BMI, an often observed side effect of AP drugs (Tarricone et al., 
2010; McEvoy et al., 2013; Bak et al., 2014). AP drugs should be considered 
not only as a risk factor for insufficient physical activity and poor physical fit-
ness (Vancampfort et al., 2016) but also as dysregulation factors for hormones 
that control appetite and food intakes, such as insulin, leptin, and adiponectin 
(Sentissi et al., 2008). Additionally, they function as factors that cause altera-
tions in biosynthesis and regulation of fatty acids (Polymeropoulos et al., 2009), 
cellular bioenergetics (Cao et al., 2019), and inflammatory marker levels 
(Fraguas et al., 2019). 
 
 
6.1.3. Biomarker profile differences between FEP patients after 
7-month treatment with APs and CSs  
Simultaneous measurement of inflammatory and metabolic factors after the 7-
month AP treatment demonstrated that markers showing an initial increase (i.e., 
EGF, ferritin, IL-6, IL-4, PAI-1, and resistin) or a decrease (i.e. leptin) returned 
to CSs level. However, several cytokines – IL-1α, IL-1β, IL-2, INF-γ, and the 
level of C-peptide – showed an increase levels in treated FEP patients were 
compared to CSs. A significant number of studies have attempted to determine 
whether there are differential cytokine profiles in individuals with the psychotic 
disorder after AP treatment. Elevated levels of INF-γ, IL-1 family cytokines, 
and IL-2 are frequently noted in meta-analyses when AP treated patients with a 
psychotic disorder are compared to CSs (Potvin et al., 2008; Miller et al., 2011; 
Goldsmith et al., 2016). Some studies have suggested that specific biomarker 
alterations in SCH are associated with psychopathology. Gonzáles-Blanco et al. 
(2019) suggested that the level of IL-2 is associated with the severity of the 
motivation and pleasure domain of negative symptoms and the level of IL-1β 
predicts the severity of the general symptomatology score.  
Regarding the effects of the AP drugs on the glucose metabolism, the 
existing studies consistently report metabolic disturbances which are characte-
rized by a complex association between the elevated level of C-peptide, hyper-
insulinemia and insulin resistance.  
Additionally, no differences in ACs levels were detected between the post-
treatment status of FEP patients and CSs in this study.  
 
 
6.2. Differences in the level of biomarkers in the chronic 
phase of the SCH spectrum disorders 
The chronic stage of SCH is characterized by a constant or repeated exacerba-
tion of psychotic symptoms after a short-term or long-term disease remission. In 
a meta-analysis, Vancampfort et al. (2013) found that multi-episodic patients 
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with SCH had an increased risk of cardio-metabolic disorders (abdominal 
obesity, hypertension, low level of HDL-c, hypertriglyceridemia, MetS, and 
diabetes) compared to CSs. Moreover, chronic low-grade inflammation is as-
sociated with both mental and cardiovascular disorders (de Rooij et al., 2009).  
 
 
6.2.1. Changes in inflammatory markers in patients with the 
chronic phase of the SCH spectrum disorders 
In our study, the most prominent elevation in patients was detected in the levels 
of pro-inflammatory markers IL-2, IL-6, IL-8, IFN-γ, and MCP-1 and the anti-
inflammatory marker IL-10 when compared to CSs. Similarly, the INF-γ/IL-4 
and INF-γ/IL-10 ratios were significantly higher in SCH patients compared to 
CSs. Contrary, the ratio of IL-2/INF-γ was significantly lower in the patient 
group.  
Similarly to our results, in several studies increased blood levels of IL-6 
have been described as  one of the most frequently confirmed immunological 
characteristics associated with SCH (Miller et al., 2011; Pillinger et al., 2019b), 
although contradictory findings have also been reported (O’Brien et al., 2008). 
IL-6 plays a critical role in the pathogenesis of inflammatory disorders and the 
physiological homeostasis of neural tissue. Preclinical studies have demon-
strated that, on the one hand, IL-6 has trophic effects on glial cells (Kahn & 
Vellis, 1994) and on the other hand, elevated levels of IL-6 disrupt neuronal 
function by enhancing neurotoxicity via an increase of intracellular calcium 
level during NMDA receptor activation (Qiu et al., 1998, Nelson et al., 2004). 
Thus, IL-6 has both neurotrophic and neurotoxic effects on different neural cell 
types and at different developmental stages. Additionally, IL-6 impacts the 
hypothalamic-pituitary-adrenal axis and stimulates the release of several hormo-
nes from the hypophysis (Spangelo et al., 1989). Evidence suggests that in 
addition to providing communication between immune cells, specific cytokines 
play a role in signaling the brain to produce neurochemical, neuroendocrine, 
neuroimmune, and behavioral changes (Kronfol & Remick, 2000). Studies have 
confirmed that the interaction between these complex systems is disrupted in 
patients with SCH (Perkovic et al., 2017).  
IL-6 has a close functional relationship with IL-2 and TNF-α (Müller et al., 
1999). These biomarkers mediate immune and inflammatory responses and 
activate cytokines that seem to play a key role in the CNS. They are actively 
transported into CNS but are also released from the activated astrocytes and 
microglia cells (Müller et al., 2000). Results from this study confirm the close 
interplay between elevated levels of INF-γ, IL-2, IL-6, IL-10, and the decreased 
level of TNF-α. IL-2 has an essential role in the key functions of the immune 
system, primarily via its direct effect on T cells. Elevated serum levels of IL-2 
are consequences of the activated macrophages and T-cells induced by chronic 
inflammation (Smith, 1991). Furthermore, IL-2 is a potent modulator of 
dopamine activity in the mesocorticolimbic and mesostriatal systems (Zalcman 
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et al., 1994). Several studies have pointed out altered peripheral levels of IL-2 in 
SCH when compared with CSs (Arolt et al., 2000; Zhang et al., 2002; Potvin et 
al., 2008). Moreover, associations between IL-2 and different groups of symp-
toms including negative symptoms and cognitive performance of SCH (Ase-
vedo et al., 2014), and associations between elevated cerebrospinal fluid levels 
of IL-2 and the recurrence of psychotic symptoms have been described 
(McAllister et al., 1995). Therefore, researchers have suggested that the effect 
of IL-2 on the central dopaminergic system may contribute to developing 
psychotic symptoms. However, data suggest that cerebrospinal fluid or blood 
IL-2 levels are different in varied biological subtypes and stages of SCH.  
In this study, serum IL-8 levels were significantly elevated in the patient 
group. In most studies, it has been found that IL-8 levels were more elevated in 
patients with a SCH spectrum disorders than in the CSs (Kaminska et al., 2001; 
Kuloglu et al., 2011). IL-8 is a characteristic member of the chemokine family. 
It is released from monocytes, macrophages, endothelial cells, and activated T 
cells. Zhang and colleagues (2005) demonstrated that IL-8 secretion is increased 
by OxS and suggested that in addition to its known proinflammatory properties, 
IL-8 might have a tissue-protective activity and a role in tissue remodeling 
during the resolution of inflammation. Furthermore, IL-8 has been shown to be 
associated with obesity (Sharabiani et al., 2011).  
In this study, levels of TNF-α could not define patients from CSs. However, 
TNF-α was found to be associated with SCH in the multivariate model. TNF-α 
is released from primarily stimulated monocytes and macrophages and it is a 
multifunctional proinflammatory cytokine. It plays an important role in linking 
the complex events involved in inflammation and immunity (Strieter et al., 
1993). Several studies have reported elevated levels of TNF-α (O’Brien et al., 
2008; Goldsmith et al., 2016) among patients with SCH, and some studies have 
demonstrated either decrease (Francesconi et al., 2011) or no change in TNF-α 
levels (Pedrini et al., 2012; Lv et al., 2015). Low sample sizes, different 
methods of cytokine measurement, engaging patients with different disease 
stages and disease duration, and various sociodemographic characteristics of the 
study populations may be some reasons for the diverging results.  
Meta-analyses have found that the blood levels of IFN-γ were elevated in 
patients with SCH compared to CSs (Miller et al., 2011; Goldsmith et al., 
2016). In contrast, Potvin et al. (2008) concluded that the INF-γ level did not 
change, and other studies have found that INF-γ levels are significantly lower in 
patients with SCH (Arolt et al., 2000; Na et al., 2007). Inconsistencies in INF-γ 
levels suggest that immune activation in subgroups of patients may be part of 
the underlying pathophysiologic process of SCH spectrum disorders. It is 
known that IFN-γ is mainly secreted by activated T-cells and it can stimulate 
the activation of macrophages, activate the orchestration of the innate immune 
system, coordinate the interaction of lymphocytes with endothelium, regulate 
type 1 T helper/type 2 T helper cells (Th1/Th2) balance and control cell proli-
feration and apoptosis (Schroder et al., 2004; Mattyasovszky et al., 2017). 
Furthermore, high levels of IFN-γ may lead to CNS inflammation and damage 
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to oligodendrocytes, and this may be one of the reasons why there is a switch 
from cellular to humoral Th2 immunity in patients with SCH (Dimitrov et al., 
2014). INF-γ is found in neuronal synapses and it may act at the level of the 
synapse to influence brain function (Garay & McAllister, 2010). Additionally, 
this cytokine plays an important role in the kynurenine pathway, as it is con-
sidered to be the main inducer of IDO, one of the enzymes that convert trypto-
phan to kynurenine in one of the first steps of the kynurenine pathway. It is 
generally suggested that diseases, where microglia are activated, favor the pro-
duction of 3-hydroxykynurenine and quinolinic acid, whereas suppression of 
this branch or astrocyte activation may favor kynurenine acid (KYNA) synthe-
sis (Campbell et al., 2014). KYNA acts in the brain as a glycine-site NMDA 
receptor antagonist, a key in the glutamatergic neurotransmission system, which 
is thought to be involved in the pathophysiology of SCH (Plitman et al., 2017).   
Based on the data from this study, the serum Th1/Th2 ratios (i.e., expressed 
as ratios of INF-γ/IL-4 and INF-γ/IL-10) examined in subjects with SCH were 
higher than those of their healthy counterparts. At individual serum cytokine 
levels, patients with SCH as a whole group had elevated levels of INF-γ and IL-
10, but lower average serum levels of IL-4. This reflects the pro-inflammatory 
activity of the immune system. Our results are consistent with studies in which 
researchers found an elevation of IL-10 levels in SCH patients (Kunz et al., 
2011). IL-10, a pleiotropic Th2 cytokine with immune-regulatory functions, 
maintains the balance between pro- and anti-inflammatory cytokines (Murray, 
2006). Increased levels of IL-10 may reflect a compensatory or counter-regu-
latory mechanism in response to the elevated levels of proinflammatory cyto-
kine levels (Yilmaz et al., 2014). Previous studies have shown that IL-10 levels 
were positively correlated to the severity of clinical symptoms of schizophrenia 
(Xiu et al., 2014). Moreover, a meta-analysis demonstrated that there might be 
an association between single nucleotide polymorphisms of IL-10 and suscepti-
bility to SCH (Gao et al., 2014). Also, regardless of IL-10 anti-inflammatory 
properties, its elevated concentration increases the risk of future cardiovascular 
events (Lakoski et al., 2008). In our sample, patients with a chronic SCH 
spectrum disorders were predominantly in a pre-diabetic/diabetic state, which 
may contribute to the expression of Th1 cytokines (Xia et al., 2017).  
MCP-1 is a well-studied chemokine, but the findings are contradicting. 
Studies have demonstrated significantly higher (Dimitrov et al., 2013; Lin et al., 
2017) or similar (Domenici et al., 2010) results between patients with SCH and 
CSs. In this study, an increase in the level of MCP-1 in patients with SCH 
spectrum disorders emerged compared to CSs. MCP-1 is one of the key 
chemokines that regulate migration and infiltration of monocytes/macrophages 
during inflammation (Deshmane et al., 2009). Pro-inflammatory substances, 
including MCP-1, can disrupt the integrity and affect the permeability of the 
BBB (Yao & Tsirka, 2014). Additionally, blood glucose, OxS, and proinflam-
matory cytokines, among other biomarkers, may up-regulate the expression of 
MCP-1 (Tesch, 2008). Increased serum MCP-1 level correlates with markers of 
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cardiovascular diseases and metabolic disorder including obesity, insulin resis-
tance, and T2DM (Panee, 2012). 
 
 
6.2.2. Changes in metabolic protein markers in patients with the 
chronic phase of the SCH spectrum disorders 
In this study, patients mean BMI was 27.9. Many factors may contribute to 
weight gain in patients with a chronic psychotic disorder: sedentary lifestyle, 
unhealthy food habits, genetic susceptibility and AP treatment are considered 
the main reasons. Meta-analyses have constantly confirmed that almost all APs 
cause weight gain (Spertus et al., 2018; Huhn et al., 2019). APs are among the 
most obesogenic medications and this indirect mechanism is coherent with our 
understanding of the pathophysiology of the development of MetS and T2DM 
(Whicher et al., 2018). At the same time, studies have indicated that rates of in-
sulin resistance, impaired glucose tolerance, hyperinsulinemia, and dyslipide-
mia are also high in patients who have not used APs (Chadda et al., 2013; 
Pillinger et al., 2017). The prevalence of MetS in patients with SCH was found 
to be ranging from 3.3% to 68.0% (Chadda et al., 2013). In this study, 32.4% of 
our patients with chronic psychotic disorder were in a pre-diabetic or diabetic 
state. According to international clinical guidelines, HbA1c is a reliable marker 
for assessing both the pre-diabetic and diabetic state of a patient (American 
Diabetes Association, 2018; Davies et al., 2018). Mean HbA1c level in our 
sample of patients with SCH spectrum disorders was close (5.90±0.10) to the 
diabetic state (ERV for HbA1c is above 6.0%). Furthermore, in this study, 
patients’ elevated level of HbA1c was associated with increased levels of INF-γ, 
IL-2 and IL-6. As a result, the pro-inflammatory state was a significant pre-
dictor of the higher HbA1c levels in our patient sample. What is more, in our 
study, the mean ratio of TGs/HDL-c was higher (1.74±0.14) than ERV  
(≤1.7 mmol/l) among patients as compared to CSs. Studies have shown that 
TGs/HDL-c ratio is a highly significant predictor of cardiovascular disease, and 
it is also independently related to insulin resistance, obesity and MetS (Grundy 
et al., 2004). Also, compared with ERV, patients had increased dyslipidemic 
parameters of cardiometabolic risk such as LDL-c and TGs, ratios of LDL-
c/HDL-c and TGs/HDL-c. In our study, patients with chronic SCH spectrum 
disorders were mostly overweight and had a prediabetic/diabetic state and had 
elevated levels of low-grade inflammatory markers. There is substantial clinical 
evidence that an increase in proinflammatory mediators in patients with SCH 
spectrum disorders initiates changes in glucose and lipid metabolism and there-
by contributes to insulin resistance (Leonard et al., 2012). Given the high pre-
valence of the MetS in patients with SCH, the timely identification of cardio-
metabolic risk factors using candidate biomarkers and subsequent treatment can 
improve the quality of life of patients and reduce health care costs (Shakeri et 
al., 2016). 
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Schematic overview of the main findings of this study is presented in Figure 
3, which reflects changes in biomarkers in accordance with a hypothetical sepa-
ration at the stage of clinical manifestation of SCH spectrum disorders. It is 
important to note that the results of our studies indicate the presence of changes 
in the biomarkers of inflammation before and after treatment with AP drugs. 
Important links between inflammation and MetS are ACs, which determine the 
pattern of energy metabolism, namely beta-oxidation of fatty acids. During the 
chronic stage of SCH spectrum disorders, the risk of cardio-metabolic disorders 
increases, therefore, an algorithm based on regular monitoring of HbA1c, 
TGs/HDL-c ratio and levels of pro-inflammatory markers could help to prevent 
or delay diabetes and cardiovascular diseases and thereby reduce premature 




FEP ‒ first-episode psychosis; 7AP ‒ 7-month antipsychotic drug treatment; SCH ‒ schizo-
phrenia; IP ‒ inflammation profile ; Anti-inf ‒ anti-inflammation; Pro-inf ‒ pro-inflammation; 
EGF ‒ epidermal growth factor; VEGF ‒ vascular endothelial growth factor; PAI (plasminogen 
activator inhibiitor)-1; IL (interleukin)-2, IL-4, IL-6, IL-8, IL-10; Inf-γ ‒ interferon-gamma; MP ‒ 
metabolic profile; ACs ‒ acylcarnitines; LCACs ‒ long-chain acylcarnitines; SCACs ‒ short-
chain acylcarnitines; HbA1c ‒ glycated hemoglobiin; BMI ‒ body mass index; TGs/HDL-c ‒ 
triglycerides/high-density lipoprotein cholesterol ratio.  
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7. STRENGTHS AND LIMITATIONS 
Before summarizing the results of this thesis, the following methodological 
issues, participant sample characteristics, and limitations should be considered.  
The first issue concerns the recruitment of subjects that was based on oppor-
tunity rather than random sampling. Subjects in the control group came from a 
sub-population and the results can therefore not be generalized to the entire 
Estonian population (Paper I, II, III). Secondly, the recruited patients formed a 
small cohort due to the rarity of AP-naїve FEP patients. They were hetero-
geneous in terms of their diagnosis, drug treatment, and duration of illness with-
out treatment – something that was difficult to avoid among any sample of 
patients with FEP (Paper I, II). Thirdly, it was not possible to control the even-
tual effects of any particular pharmacological agent on the measured putative 
biomarkers due to our small sample size and the fact that different types of 
treatment drugs were used during the observation period. For this reason, we 
analyzed the main effects of AP treatment at the group level (Paper I, II). 
Fourthly, we collected data from CSs at a single time point and did not control 
their health condition or metabolic and inflammatory biomarker levels after the 
same follow-up period as was done for the FEP patient group (Paper I, II). 
Fifthly, we did not evaluate either the participant's dietary or physical activity 
habits. This is worth mentioning, since the chronicity of the disease and conti-
nuous AP treatment may adversely affect lifestyle factors in patients with a 
psychotic disease (Paper I, II, III). Sixthly, the naturalistic and cross-sectional 
nature of the survey did not permit us to study the temporal relationships 
between the treatment effects and the inflammatory or cardio-metabolic risk 
markers in patients with a chronic psychotic disorder (Paper III). Seventhly, we 
used EVR to establish disturbances in well-known cardiometabolic risk marker 
levels among SCH patients, because these data were not available for our CSs 
sample (Paper III).  
Although the findings should be interpreted with caution, this study has 
several strengths.  
Firstly, we used naturalistic study design and no restrictions were applied in 
regard to patients’ treatment or other clinically relevant decisions (Paper I, II, 
III). Second strength is the longitudinal study design (Paper I, and Paper II), 
which allowed to discover associations between variables that are not related to 
various FEP patients background characteristics. Thirdly, dropout rate among 
enrolled FEP patients during the study period was very low (5%), only two 
patients refused to take APs and they were excluded from the follow-up ana-
lysis (Paper I, II). Fourthly, this study represents comprehensive and simulta-
neous examination of the inflammatory and metabolic biomarkers in patients 
with SCH spectrum disorders compared to CSs (Paper I, II, III). Fifthly, we 
used well-known and well-validated techniques to define biomarker levels and 
laboratory tests were performed following standard procedures and quality 
controls (Paper I, II, III). Sixthly, we used relevant covariates (i.e., BMI, 
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smoking status, age, etc.) in statistical analyses, which allowed to account for 
natural heterogeneity in the population (Paper I, II, III). Finally, results of this 
study emphasize the value of measurement of dynamic biomarker profiles at 




8. CLINICAL RELEVANCE 
According to the results, there is a close relationship between the immune and 
metabolic processes that influence the development of the MetS in patients with 
SCH spectrum disorders. Thus, monitoring inflammatory and metabolic bio-
markers in patients with FEP (before and during the AP treatment) and in 
patients with the chronic stage of SCH helps to assess the likelihood of them 
developing cardio-metabolic disorders and select patients who need interven-
tions, thereby making it possible to improve the quality of life and prolong the 
years of life of the patients. Despite the proven efficacy of APs to treat psycho-
tic symptoms, these medications have unwanted effects on metabolism. Weight 
gain may be one of the reasons for poor drug compliance; obesity may induce a 
prolonged state of low-grade inflammation and thereby lead to increased cardio-
metabolic complications and mortality. It can be argued that the imbalance 
between metabolism and the immune system is a characteristic feature of the 
endo-phenotype of SCH spectrum disorders, regardless of the stage of the 
disease. In our studies, altered levels of low-grade inflammatory markers and 
ACs were identified in AP-naïve patients with FEP and further AP treatment 
caused unwanted side effects in metabolism. The results of our study and other 
similar studies highlight the importance of putative biomarker profile assess-
ments and multidisciplinary management of medical and behavioral conditions 
in patients with SCH spectrum disorders at different stages of the disease. The 
risks and benefits of individual APs should be carefully considered when 




9. IMPLICATIONS FOR FURTHER RESEARCH 
SCH spectrum disorders are etiologically and pathophysiologically hetero-
geneous diseases, that varies widely in clinical manifestation, course of progres-
sion and maybe even biomarker profiles from person to person. Thus, there is 
need to move toward a more personal approach, which could allow to define 
treatment-relevant subtypes of the disorder. Biomarker-profiles diagnostic and 
treatment utility should be better implemented for clinical practice. Identifica-
tion and characterization of biomarkers are crucial first steps in this process. 
Future research in larger samples could demonstrate linkage between putative 




This dissertation presents a comprehensive investigation into the changes of in-
flammatory and metabolic candidate biomarkers in SCH spectrum disorders in 
different stages of the disease. 
The conclusions are as follows:  
1. Significantly elevated levels of EGF, IL-2, IL-4, IL-6, ferritin, resistin, and 
PAI-1 as well as decreased levels of leptin, and IL-1β emerged when AP-
naïve FEP patients were compared to CSs. A 7-month AP-treatment reduced 
the shifts in biomarkers mentioned above. The most salient changes emerged 
in the levels of EGF, ferritin, PAI-1, IL-4, and IL-6. At the same time, AP 
treatment was accompanied by elevated serum levels of C-peptide, leptin 
and reduced level of adiponectin.  
 
2. Simultaneously with previously described elevated levels of EGF, IL-4, IL-
6, ferritin, resistin, PAI-1, and decreased levels of leptin and IL-1β, drug-
naïve FEP patients had elevated serum levels of LCACs (i.e. C14:1, C16, 
C16:1 and C18:1) and reduced level of SCAC (C3) as compared to CSs. 
After a 7-month AP treatment of FEP patients, the established shift in EGF, 
and proinflammatory biomarkers returned to the corresponding levels of 
CSs. In addition to previously mentioned metabolic protein biomarker shifts, 
LCACs (C16, C18) levels were diminished and SCACs (C3, C5) levels were 
increased during the AP treatment. The results demonstrated that AP-naïve 
patients with FEP had low-grade inflammatory state which was reversed by 
the 7-month AP treatment. The impact of the treatment was concurrently 
associated with unwanted side effects on metabolism. Results confirmed that 
there is a disease stage and AP treatment dependent interplay between 
inflammatory, metabolic protein biomarkers and ACs in patients with FEP. 
  
3. Patients with a chronic stage of the SCH spectrum disorders displayed the 
most prominent elevation in the levels of pro-inflammatory markers IL-2, 
IL-6, IL-8, IFN-γ, MCP-1 as well as the anti-inflammatory marker IL-10 
compared to CSs. The INF-γ/IL-4 and INF-γ/IL-10 ratios were significantly 
higher in SCH patients indicating a significant shift towards a pro-inflam-
matory state compared to CSs. These results demonstrated that patients with 
SCH had specific low-grade inflammatory biomarker profiles independent of 
gender or age. Furthermore, higher levels of IL-2, INF-γ, and IL-6 and lower 
levels of MCP-1 were significant predictors of increased HbA1c in the group 
of patients with SCH spectrum disorders. These results confirmed a link 
between persistent low-grade inflammation and an increase in HbA1c in 
chronic SCH patients. Moreover, there was a strong relationship between 
increased value of the ratio of typical cardiometabolic risk marker 
(TGs/HDL-c) and elevated levels of INF-γ, HbA1c, and LDL-c as well as 
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reduced levels of IL-4 and IL-10. The results demonstrated that the chronic 
stage of the psychotic illness is accompanied by low-grade inflammation and 
patients with SCH spectrum disorders have an increased risk of metabolic 
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SUMMARY IN ESTONIAN 
Immuun- ja metaboolse süsteemi vastastikune mõju 
skisofreeniaspektri häire erinevates staadiumides 
Skisofreeniaspektri häired on rasked ja kroonilised psühhootilised haigused, 
millel on tugev bioloogiline alus. Haigus avaldub tavaliselt noores täiskasvanu-
eas ja kestab terve elu ning seda iseloomustavad olulised tegelikkuse tunneta-
mise ja käitumishäired, millega võib kaasneda toimetuleku alanemine.  
Epidemioloogilised ja geneetilised uuringud  on näidanud metaboolse ja 
immuunsüsteemi rolli skisofreeniaspektri häirete avaldumise ja kulu etiopato-
geneesis. Nii esmast psühhootilist episoodi (EPE) kui ka kroonilist haiguse staa-
diumi on seostatud kesknärvisüsteemi (KNS) toimimist mõjutava kogu organis-
mi immuunsussüsteemis ilmnevate eripäradega. Haigusega kaasnevat immuunsus-
süsteemi talitlushäire olemasolu kinnitab mikrogliia aktivatsioon ajus ning tsüto-
kiinide ja muude põletikuliste markerite muutunud tase seljaajuvedelikus ja 
veres. Meta-analüüsid kinnitavad, et nii ravinaiivsete EPE patsientide kui ka 
kroonilise haiguse ägenemisfaasis olevate patsientide vereseerumis on põletikku 
soodustavate tsütokiinide (nt. interleukiin-(IL)1β, IL-6) tasemed tõusnud ning 
põletikuvastase tsütokiini IL-10 sisaldus on langenud. Lisaks on leitud selliste 
põletikuliste protsessidega seotud kasvufaktorite nagu veresoonte endoteeli 
kasvufaktori (VEGF) ja epidermaalse kasvufaktori (EGF) seerumitaseme 
nihkeid psühhoosihaigetel. Samaaegselt on populatsioonipõhised longitudinaal-
uuringud näidanud verest mõõdetud IL-6 kõrgenenud taseme seost südame-
haigusega ja II tüüpi suhkurtõvega ning skisofreeniaspektri häiretega inimestel 
esineb sageli kaasuvate haigustena nimetatud eluiga lühendavaid kehalisi hai-
gusi. Tsütokiinid on tihedalt seotud ka oksüdatiivse stressiga kaasneva vabade 
radikaalide tekkimisega organismis, mis aktiveerivad hüpotalamuse-hüpofüüsi-
neerupealiste telge. See omakorda põhjustab muutusi suhkru ja rasvhapete aine-
vahetuses, tuues kaasa raku jõujaamade ehk mitokondrite talitlushäireid ja 
madalaastmelise põletiku püsimise kogu kehas. Kogunenud tõendusmaterjal 
näitab, et skisofreeniaspektri häired seonduvad rasvhapete häirunud ainevahetu-
sega KNS-is ja metaboolse sündroomi (MetS) kõrge suhtarvuga. Kroonilise 
psühhootilise häirega patsientide vereseerumis on tuvastatud muutuseid 
lipiidide, fosfolipiidide, triglütseriidide (TGd) ja kolesterooli tasemetes. Rasv-
happed lagundatakse mitokondrites beetaoksüdatisooni tulemusena. Rasvhapete 
aktiivvormideks on atsüülkarnitiinid (AKd), mille profiili analüüsi kasutatakse 
beetaoksüdatsioonihäirete tuvastamiseks. Sõltuvalt süsinikuahela pikkusest 
eristatakse pika-, keskmise- või lühikeseahelalisi AKde. Varasemad uuringud 
on näidanud, et AKd on seotud insuliintundlikkusega, rasvhapete metabolis-
miga, põletikulise vastusega, oksüdatiivse stressi ja bioenergeetiliste funktsioo-
nidega. Lisaks on psühhootilise häire erinevates staadiumides leitud teiste 
hulgas nt. glükoosi, insuliini, C-peptiidi, leptiini, adiponektiini, resistiini ja 
teiste ainevahetuse toimimist peegeldavate biomarkerite tasemete nihkeid.  
84 
Tuginedes varasematele teadustulemustele on põletikuliste ja ainevahetus-
like eripärade uurimine skisofreeniaspektri häirete erinevates staadiumides jät-
kuvalt suure tähtsusega. Sedalaadi uuringud pakuvad lisanduvat teavet haiguse 
olemuse ja kulu mõistmiseks ning võimaldavad vältida antipsühhootilise (AP) 
raviga kaasneda võivaid ebasoovitavaid kõrvaltoimeid.  
 
Uurimistöö eesmärgid 
Antud doktoritöö keskendus põletiku ja ainevahetuse nihete uurimisele EPE 
patsientidel enne AP ravi alustamist ja 7-kuulise AP ravi järgselt ning krooni-
lises haiguse staadiumis olevatel patsientidel AP ravi foonil.  
Uurimistöö eesmärgid:  
1. Hinnata põletiku ja metabolismimarkerite tasemete erinevuste olemasolu 
EPE patsientide vereseerumis enne ja pärast 7-kuulist AP ravi võrreldes 
kontrollgruppi kuulujatega. 
2. Iseloomustada põletiku-, metabolismimarkerite ja AKde profiilide koostoi-
mete kaudu seisundist tulenevat bioenergeetilist düsfunktsiooni EPE patsien-
tidel enne ja pärast 7-kuud kestnud AP ravi võrreldes kontrollgruppi kuulu-
jatega.   
3. Tuvastada madalaastmelised põletikulised ja ainevahetuslikud nihked kroo-
nilises staadiumis olevate skisofreeniaspektri häirega patsientidel võrreldes 
kontrollgruppi kuuluvate isikutega. 
 
Uuritavad ja meetodid 
Uurimisprojekt kooskõlastati Tartu Ülikooli inimuuringute eetika komiteega. 
Kõik uuritavad andsid kirjaliku informeeritud nõusoleku uuringus osalemiseks. 
Patsiendid kaasati Tartu Ülikooli Kliinikumi psühhiaatriakliinikusse ravile 
pöördunud EPEga patsientide hulgast ning kroonilises staadiumis olevad pat-
siendid hõlmati Kesk-Eestis, Jõgeva maakonnas asuvas Võisiku hooldekodus 
viibivate isikute seast. Kontrollgrupi moodustasid eakaaslased, kellel enesel ega 
lähisugulasel ei esinenud psühhootilist või muud rasket psüühikahäiret või 
kehalist haigust.   
EPEga patsientide valimi moodustasid 38 isikut (21 meest ja 17 naist), kelle 
keskmine vanus oli 25,4±0,9 aastat, neil oli esmakordselt diagnoositud psüh-
hootilise episoodi avaldumine ning nad polnud varasemalt tarvitanud AP ravi. 
Isikud arvati uuringust välja, kui psühhootilise häire avaldumise põhjuseks oli 
psühhoaktiivsete ainete tarvitamine või neil esines kaasuvana raske põletikuline 
haigus. Psühhiaatrilised diagnoosid põhinesid kliinilisel küsitlusel vastavalt 
Rahvusvahelise Haiguste Klassifikatsiooni 10. väljaandele (RHK-10). EPEga 
patsientide AP ravi toimus vastavalt raviarsti valikule ning jälgimisperioodi 
jooksul võis raviarst raviannused või APi toimeainet kliinilisest seisundist 
tulenevalt muuta. EPEga patsientide andmeid koguti kahel ajahetkel: uuringusse 
kaasamise hetkel ja pärast jälgimisperioodi (keskmine kestus 7,2±0,7 
kuud). Kontrollgruppi kuulus 37 isikut (16 meest ja 21 naist; keskmise vanu-
sega 24,8±0,9 aastat), kelle kohta andmed koguti ühel ajahetkel.  
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Kroonilises staadiumis olevate skisofreeniaspektri häirega patsientide valimi 
moodustasid 105 isikut (45 meest ja 60 naist), kes olid stabiilses kliinilises 
seisundis ja tarvitasid regulaarselt AP ravi. Uuritavate keskmine vanus oli 
53,1±10,9 aastat ja nende haigus oli kestnud 6–52 aastat. Kontrollgruppi kulus 
148 inimest (68 meest ja 80 naist keskmise vanusega 51,3±7,6 aastat).  
Uuritavatelt koguti hommikul tühjakõhu vereseerumid. Lisaks kaardistati 
isikute demograafilised taustaandmed, mõõdeti nende pikkus ja kaal.   
Biokeemilised markereid määrati standardsete kliiniliste laboratoorsete mee-
toditega, kasutades Tartu Ülikooli Kliinikumi kliinilise labori sertifitseeritud 
analüüse. Põletiku-, metabolismi markerite ja AKde  määramiseks kasutati täna-
päevaseid rahvusvaheliselt aktsepteeritud määramismeetodeid (kõrgrõhuvedelik-
kromatograafia ja tandem-massispektromeetria kombinatsiooni, sandwich 
kemoluminestsents-immuunmeetodit ja fotokolorimeetria tehnikaid).  
 
Uurimistöö tulemused ja järeldused 
Antud uurimistöös hinnati põhjalikult põletiku ja metaboolsete biomarkerite 
muutusi skisofreeniaspektri häirete erinevates staadiumides.  
Uurimistöö tulemusel selgus:  
1. AP ravi eelselt olid EPEga patsientidel EGF, IL-2, IL-4, IL-6, ferritiini, 
resistiini ja PAI-1 sisaldused seerumis tõusnud ning IL-1ß ja leptiini tasemed 
olid langenud võrreldes kontrollgruppi kuulujatega. 7-kuuline AP ravi kõr-
valdas eelnevalt kirjeldatud biomarkerite tasemete nihked ning kõige silma-
torkavamad muutused ilmnesid EGFi, ferritiini, PAI-1, IL-4 ja IL-6 tasemete 
osas. Samas, AP-ravi tõi esile C-peptiidi ja leptiini suurenenud sisalduse 
ning adiponektiini taseme languse patsientide vereseerumis.  
 
2. Võrreldes kontrollgruppi kuulujatega oli EPE-ga patsientidel AP ravi eelselt 
ilmnenud EGFi, IL-4, IL-6, ferritiini, resistiini ja PAI-1 seerumsisalduse tõus 
ja IL-1ß ja leptiini langus seotud samaaegselt esinenud pikaahelaliste AK-de 
(sh. C14:1, C16, C16:1 ja C18:1) sisalduse tõusu ning lühikeseahelalise AKi 
(C3) taseme langusega seerumis. 7-kuuline AP ravi soodustas  patsientidel 
EGFi ja põletikuliste markerite tasemete pöördumise kontrollgruppi kuulu-
jatega sarnasele tasemele, kuid tõi kaasa metaboolsete markerite ebasoovitud 
nihetele lisaks ka lühikeseahelaliste AKde (C3, C5) taseme tõusu ja pika-
ahelaliste AK-de (sh. C16, C18) taseme languse seerumis.   
Tulemused näitasid, et ravieelses seisundis kaasneb EPEga madala 
raskusastmega krooniline põletik, mis 7-kuulise AP-ravi foonil taandub, kuid 
ravi toob samaaegselt kaasa olulised negatiivsed efektid ainevahetuse toimi-
misele. Tõendust leidis, et põletikuliste ja metaboolsete markerite ning AK-
de vahel on haigusprotsessist ja AP-raviefektist tulenev koostoime. 
 
3. Skisofreeniaspektri häire kroonilises staadiumis olevate haigete vereseeru-
mis on võrreldes kontrollgruppi kuulujatega kõrgenenud järgnevate põletik-
ku soodustavate: IL-2, IL-6, IL-8, IFN-γ, MCP-1 ja põletikuvastase markeri 
IL-10 tasemed. Biomarkerite omavaheliste suhete (INF-γ/IL-4 ja INF-γ/IL-
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10) keskmised väärtused olid patsientidel märkimisväärselt kõrgemad, mis 
näitab olulist nihet põletikulise seisundi suunas võrreldes kontrollgruppi 
kuulujatega. Need tulemused kinnitavad, et skisofreeniaspektri häirega 
patsientidel esineb kroonilises haiguse staadiumis, sõltumata soost või vanu-
sest, püsiv madala raskusastmega põletik. Lisaks, IL-2, INF-γ, IL-6 kõrgem 
ning MCP-1 madalam tase olid seotud kõrgenenud HbA1c tasemega, mis 
pakub tõendust seose olemasolust püsiva madalaraskusastmega põletiku ja 
glükoosiainevahetushäire vahel kroonilise haigusstaadiumiga patsientide 
grupis. Patsientide grupis ilmnes kardio-metaboolsete häirete riskimarkeri 
(ehk suhte TGd/HDL-kolesterool) kõrgenenud väärtus, mis oli seotud põle-
tikku soodustava markeri INF-γ sisalduse tõusuga (võrreldes põletikuvas-
taste markerite IL-4 ja IL-10 tasemetega) ning kõrgenenud HbA1c ja LDL-
kolesterooli väärtustega. Tulemused näitasid, et skisofreeniaspektri häire 
kroonilises staadiumis olevatel haigetel püsib kehas madalaastmeline kroo-
niline põletik ning neil esineb kõrgenenud risk haigestuda ainevahetus-
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APPENDIX 
Table A-1. Identification of differences in serum cytokines, growth factor, metabolic 
biomarkers (pg/mL), and acylcarnitine levels (µmoles/mL) between first-episode psychosis 














(Ƞ2) Median        
(min–max) 
Median       
(min–max) 
Inflammatory markers and growth factor 
IL (Interleukin)-1αa 0.20 (0.06 – 1.33) 
0.16 
(0.06 – 0.60) 0.42 ns - 
IL (Interleukin)-1αb 0.30 (0 – 1.78) 
0.32 
(0.20 – 1.67) -1.29 ns - 
IL-1βa 1.29 (0.44 – 3.44) 
1.91 
(0.45 – 4.47) -3.02 0.003 0.12 
IL-2a 3.04 (1.18 – 3.99) 
2.81 
(1.34 – 4.49) 3.18 0.001 0.13 
IL-4a 1.70 (1.02 – 3.75) 
1.30 
(0.96 – 2.84) 3.18 0.001 0.13 
IL-6a 1.07 (0.33 – 5.03) 
0.60 
(0.13 – 1.93) 3.17 0.002 0.13 
IL-6b 0.84 (0.12 – 8.64 
0.53 
(0.23 – 1.54) 2.53 0.01 0.09 
IL-8a 5.25 (1.61 – 10.95) 
5.29 
(1.72 – 17.87) 0.02  ns - 
IL-10a 0.45 (0.19 – 1.51) 
0.51 
(0.19 – 1.35) 0.21 ns - 
INF-γ (Interferon-γ)a 0.34 (0.20 – 0.77) 
0.30 
(0.19 – 0.53) 1.38 ns - 
TNF (Tumor necrosis factor)- αa 1.88 (1.01 – 7.56) 
1.70 
(0.86 – 8.70) 0.42 ns - 
TNF (Tumor necrosis factor)- αb 5.43 (2.92 – 10.73) 
5.17 
(3.42 – 8.73) 0.13 ns - 
PAI-1  
(Plasminogen activator  
inhibitor-1)b 
25.68 
(8.92 – 48.58) 
21.35 
(7.57 – 49.88) 2.75 0.006 0.10 
Ferritinb 56.0 (4.26 – 238.7) 
22.1 
(1.22 – 184.7) 2.86 0.004 0.11 
MCP-1 (monocyte chemoattractant 
protein -1) a 
114.22 
(23.05 – 364.61) 
104.98 
(26.02 – 358.9) 0.02 ns - 
EGF (Epidermal growth factor)a 17.55 (2.20 – 51.83) 
2.05 
(0.66 – 7.74) 6.67 <1E-6 0.59 
VEGF  
(Vascular endothelial  
growth factor) a 
32.66 
(9.7 – 148.52) 
42.84 














(Ƞ2) Median        
(min–max) 
Median       
(min–max) 
Metabolic protein markersb 
Insulin 7.30 (3.10 – 60.59) 
8.47 
(1.80 – 126.9) -0.55 ns - 
C-peptide 0.80 (0.12 – 4.48) 
1.20 
(0.37 – 2.28) -1.29 ns - 
Leptin 0.85 (0 – 2.22) 
1.41 
(0.38 – 6.69) -2.73 0.006 0.11 
Resistin 2.96 (1.69 – 8.58) 
2.66 
(1.59 – 4.10) 2.79 0.005 0.11 
Adiponectin 7336 (2093 – 12334) 
7076 
(2382 – 14273) 0.52 ns - 
Acylcarnitinesc 
C0 (Carnitine) 33.30 (18.30 – 46.60) 
32.20  
(17.30 – 52.70) 0.17 ns - 
C10 (Decanoylcarnitine) 0.31 (0.17 – 0.87) 
0.28 
(0.15 – 0.45) - 2.13 0.03 0.06 
C10:1 (Decenoylcarnitine) 0.14 (0.06 – 0.30) 
0.13 
(0.08 – 0.23) - 0.96 ns - 
C10:2 (Decadienylcarnitine) 0.06 (0.04 – 0.09) 
0.06 
(0.04 – 0.10) 0.54 ns - 
C12 (Dodecanoylcarnitine) 0.12 (0.06 – 0.32) 
0.11 
(0.06 – 0.18) -2.29 0.02 0.07 
C12-DC     
(Dodecanedioylcarnitine) 
0.13 
(0.08 – 0.15) 
0.12 
(0.11 – 0.14) -0.59 ns - 
C12:1 (Dodecenoylcarnitine) 0.13  (0.07 – 0.29) 
0.12  
(0.07 – 0.19) -2.13 0.03 0.06 
C14 (Tetradecanoylcarnitine) 0.03 (0.02 – 0.05) 
0.03 
(0.01 – 0.04) -2.44 0.02 0.08 
C14:1 (Tetradecenoylcarnitine) 0.06 (0.03 – 0.15) 
0.04 
(0.02 – 0.11) -3.34 0.0008 0.15 




(0.01 – 0.03) 
0.02 




(0.01 – 0.07) 
0.02 
(0.01 – 0.05) -3.10 0.002 0.13 




(0.01 – 0.02) 
0.01 
(0.01 – 0.02) -0.18 ns - 
C16 (Hexadecanoylcarnitine) 0.12 (0.06 – 0.20) 
0.09  





(0.01 – 0.03) 
0.01 














(Ƞ2) Median        
(min–max) 
Median       
(min–max) 
C16:1 (Hexadecenoylcarnitine) 0.03 (0.02 – 0.06) 
0.02 




(0.01 – 0.02) 
0.01  
(0.01 – 0.02) -3.42 0.0006 0.16 
C16:2 (Hexadecadienylcarnitine) 0.01 (0.01 – 0.02) 
0.01 
(0.01 – 0.02) -1.53 ns - 




(0.02 – 0.04) 
0.03  
(0.02 – 0.04) 1.08 ns  - 
C18 (Octadecanoylcarnitine) 0.05 (0.03 – 0.09) 
0.04 
(0.02 – 0.07) -2.92 0.004 0.11 
C18:1 (Octadecenoylcarnitine) 0.13 (0.05 – 0.23) 
0.09  




(0.02 – 0.05) 
0.02  
(0.01 – 0.05) -2.02 0.04 0.05 
C18:2 (Octadecadienylcarnitine) 0.04 (0.02 – 0.07) 
0.03  
(0.01 – 0.05) -3.68 0.0002 0.18 
C2 (Acetylcarnitine) 4.33 (1.73 – 14.00) 
3.96  
(1.78 – 5.96) -0.67 ns - 
C3 (Propionylcarnitine) 0.23 (0.14 – 0.49) 
0.31  
(0.13 – 0.61) 3.72 0.0002 0.19 
C3-DC(C4-OH) (Malonylcarnitine  
(Hydroxy-butyrylcarnitine)) 
0.05 
(0.03 – 0.25) 
0.04 





(0.04 – 0.11) 
0.06  
(0.04 – 0.09) -0.29 ns - 
C3-OH   
(Hydroxypropionylcarnitine) 
0.04 
(0.03 – 0.07) 
0.04  
(0.03 – 0.05) 0.88 ns - 
C3:1 (Propenoylcarnitine) 0.03 (0.02 – 0.05) 
0.03 
(0.02 – 0.04) -0.80 ns - 
C4 (Butyrylcarnitine) 0.17 (0.10 – 0.32) 
0.18 
(0.12 – 0.30) 2.63 0.008 0.09 
C4:1 (Butenylcarnitine) 0.05 (0.03 – 0.06) 
0.05 





(0.02 – 0.05) 
0.03 
(0.02 – 0.04) -3.43 0.0006 0.16 
C5 (Valerylcarnitine) 0.14 (0.10 – 0.31) 
0.17  




(0.02 – 0.04) 
0.02 




 (0.03 – 0.06) 
0.04 














(Ƞ2) Median        
(min–max) 
Median       
(min–max) 
C5:1 (Tiglylcarnitine) 0.08  (0.05 – 0.11) 
0.08 
(0.05 – 0.12) -0.17 ns  - 
C5:1-DC (Glutaconylcarnitine) 0.03  (0.02 – 0.03) 
0.03 
(0.02 – 0.04) -2.23 0.03 0.07 
C6:1 (Hexenoylcarnitine) 0.01  (0.007 – 0.01) 
0.009 
(0.006 – 0.01) -1.27 ns - 
C7-DC (Pimelylcarnitine) 0.03  (0.02 – 0.06) 
0.03 
(0.02 – 0.04) -1.75 ns  - 
C8 (Octanoylcarnitine) 0.14  (0.10 – 0.33) 
0.13 
(0.09 – 0.20) -1.48 ns - 
C9 (Nonaylcarnitine) 0.05  (0.03 – 0.08) 
0.06 
(0.03 – 0.12) 2.88 0.004 0.11 
Hexose 4291.50  (2802– 5918) 
3907.00 
(2335– 5533) -2.59 0.01 0.09 
 
Z-adjusted values according to Mann-Whitney U-test (FEPb compared to CS).  
a High-sensitive biochip array technology was used to measure levels of cytokines. 
b Metabolic biochip array technology was used to measure metabolic markers. 
c Serum level of ACs and hexoses were determined with the AbsoluteIDQ™ p180 kit.  
 
 
Table A-2. Identification of differences in serum cytokines, growth factor, metabolic 
biomarkers (pg/mL), and acylcarnitine levels (µmoles/mL) between the first-episode psychosis 















 size  
(Ƞ2) Median         
(min–max) 
Median         
(min–max) 
Inflammatory markers and growth factor
IL (Interleukin)-1αa 0.20 (0.06 – 1.33) 
0.15 
(0.08 – 1.26) 2.01 0.04 0.06 
IL (Interleukin)-1αb 0.30 (0 – 1.78) 
0.24 
(0 – 1.77) 2.47 0.01 0.11 
IL-1βa 1.29 (0.44 – 3.44) 
1.21 
(0.40 – 3.39) 1.24 ns - 
IL-2a 3.04 (1.18 – 3.99) 
2.06 
(1.14 – 3.34) 4.78 2E-6 0.32 
IL-4a 1.70 (1.02 – 3.75) 
1.35 
(0.92 – 4.32) 2.88 0.004 0.12 
IL-6a 1.07 (0.33 – 5.03) 
0.60 















 size  
(Ƞ2) Median         
(min–max) 
Median         
(min–max) 
IL-6b 0.84 (0.12 – 8.64 
0.75 
(0.23 – 1.64) 2.16 0.03 0.07 
IL-8a 5.29 (1.72 – 17.87) 
4.12 
(1.25 – 17.36) 2.17 0.03 0.07 
IL-10a 0.51 (0.19 – 1.35) 
0.47 
(0.27 – 2.10) 0.34 ns - 
INF-γ (Interferon-γ)a 0.34 (0.20 – 0.77) 
0.21 
(0.17 – 0.69) 3.21 0.001 0.16 
TNF (Tumor necrosis factor)- αa 1.88 (1.01 – 7.56) 
1.71 
(1.03 – 2.82) 1.46 ns - 
TNF (Tumor necrosis factor)- αb 5.43 (2.92 – 10.73) 
5.10 
(2.84 – 9.30) 0.01 ns - 
PAI-1  
(Plasminogen activator  
 inhibitor-1)b 
25.68 
(8.92 – 48.58) 
22.01 
(7.06 – 57.07) 2.24 0.03 0.07 
 Ferritinb 56.0 (4.26 – 238.7) 
30.9 
(4.75 – 150.0) 4.19 0.00003 0.25 
MCP-1 (monocyte 
chemoattractant protein -1) a 
104.98 
(26.02 – 358.90) 
105.91 
(10.63 – 339.55) 0.2 ns - 
EGF (Epidermal growth factor)a 17.55 (2.20 – 51.83) 
1.68 
(0.49 – 7.74) 5.16 <1E-6 0.38 
VEGF (Vascular endothelial 
growth factor) a 
42.84 
(8.28 – 147.88) 
26.34 
(4.77 – 92.29) 4.07 0.00005 0.23 
Metabolic protein markersb 
 Insulin 7.30 (3.10 – 60.61) 
10.10 
(3.03 – 66.81) 1.26 ns - 
 C-peptide 0.80 (0.12 – 4.48) 
1.90 
(0.28 – 7.71) 3.10 0.002 0.14 
 Leptin 0.85 (0 – 2.22) 
1.21 
(0 – 9.29) 3.38 0.0007 0.16 
 Resistin 2.96 (1.69 – 8.58) 
2.80 
(1.42 – 4.76) 2.61 0.009 0.10 
 Adiponectin 7335 (2093 – 2334) 
5591 
(1084 –10223) 2.43 0.02 0.12 
Acylcarnitinesc 
C0 (Carnitine) 33.30 (18.30 – 46.60) 
30.35 
(15.80 – 58.40) 0.32 ns - 
C10 (Decanoylcarnitine) 0.31 (0.17 – 0.87) 
0.22 
(0.12 – 1.08) 1.43 ns - 
C10:1 (Decenoylcarnitine) 0.14 (0.06 – 0.30) 
0.13 
(0.06 – 0.31) 0.80 ns - 
C10:2 (Decadienylcarnitine) 0.06 (0.04 – 0.09) 
0.05 















 size  
(Ƞ2) Median         
(min–max) 
Median         
(min–max) 
C12 (Dodecanoylcarnitine) 0.12 (0.06 – 0.32) 
0.09 
(0.04 – 0.28) 1.71 ns - 
C12-DC (Dodecanedioylcarnitine) 0.13 (0.08 – 0.15) 
0.12 
(0.10 – 0.16) 0.45 ns - 
C12:1 (Dodecenoylcarnitine) 0.13  (0.07 – 0.29) 
0.12 
(0.05 – 0.27) 1.63 ns - 
C14 (Tetradecanoylcarnitine) 0.03 (0.02 – 0.05) 
0.02 
(0.01 – 0.04) 2.59 0.01 0.09 
C14:1 (Tetradecenoylcarnitine) 0.06 (0.03 – 0.15) 
0.04 




(0.01 – 0.03) 
0.01 
(0.01 – 0.03) 2.29 0.02 0.07 
C14:2 (Tetradecadienylcarnitine) 0.02 (0.01 – 0.07) 
0.02 





(0.01 – 0.02) 
0.01 
(0.01 – 0.02) 1.65 ns - 
C16 (Hexadecanoylcarnitine) 0.12 (0.06 – 0.20) 
0.08 




(0.01 – 0.03) 
0.01 
(0.01 – 0.03) 1.76 ns - 
C16:1 (Hexadecenoylcarnitine) 0.03 (0.02 – 0.06) 
0.02 




(0.01 – 0.02) 
0.01 
(0.01 – 0.02) 2.62 0.009 0.10 
C16:2 (Hexadecadienylcarnitine) 0.01 (0.01 – 0.02) 
0.01 





(0.02 – 0.04) 
0.03 
(0.02 – 0.04) 0.70 ns - 
C18 (Octadecanoylcarnitine) 0.05 (0.03 – 0.09) 
0.04 
(0.02 – 0.06) 2.70 0.007 0.10 
C18:1 (Octadecenoylcarnitine) 0.13 (0.05 – 0.23) 
0.08 
(0.04 – 0.17) 4.13 0.00004 0.24 
C18:1-OH (Hydroxyoctadecenoyl-  
carnitine) 
0.03 
(0.02 – 0.05) 
0.02 
(0.01 – 0.05) 1.38 ns - 
C18:2 (Octadecadienylcarnitine) 0.04 (0.02 – 0.07) 
0.03 
(0.02 – 0.05) 3.86 0.0001 0.21 
C2 (Acetylcarnitine) 4.33 (1.73 – 14.00) 
4.11 
(2.24 – 7.72) 0.66 ns - 
C3 (Propionylcarnitine) 0.23 (0.14 – 0.49) 
0.30 
(0.14 – 0.62) 3.22 0.001 0.15 
C3-DC(C4-OH) (Malonylcarnitine  
(Hydroxybutyrylcarnitine)) 
0.05 
(0.03 – 0.25) 
0.04 















 size  
(Ƞ2) Median         
(min–max) 






(0.04 – 0.11) 
0.06 




(0.03 – 0.07) 
0.04 
(0.03 – 0.07) 0.05 ns - 
C3:1 (Propenoylcarnitine) 0.03 (0.02 – 0.05) 
0.03 
(0.02 – 0.06) 1.02 ns - 
C4 (Butyrylcarnitine) 0.17 (0.10 – 0.32) 
0.17 
(0.10 – 0.31) 0.78 ns - 
C4:1 (Butenylcarnitine) 0.05 (0.03 – 0.06) 
0.05 
(0.03 – 0.07) 0.86 ns - 
C6(C4:1-DC) (Hexanoylcarnitine  
(Fumarylcarnitine)) 
0.03 
(0.02 – 0.05) 
0.02 
(0.01 – 0.06) 2.22 0.03 0.07 
C5 (Valerylcarnitine) 0.14 (0.10 – 0.31) 
0.16 
(0.10 – 0.39) 2.51 0.01 0.09 
C5-DC(C6-OH) (Glutarylcarnitine  
(Hydroxyhexanoylcarnitine)) 
0.03 
(0.02 – 0.04) 
0.02 
(0.01 – 0.04) 2.37 0.02 0.09 
C5-M-DC (Methylglutarylcarnitine) 0.04  (0.03 – 0.06) 
0.04 
 (0.02 – 0.05) 1.00 ns - 
C5:1 (Tiglylcarnitine) 0.08  (0.05 – 0.11) 
0.07 
 (0.04 – 0.12) 1.05 ns - 
C5:1-DC (Glutaconylcarnitine) 0.03  (0.02 – 0.03) 
0.02 
 (0.01 – 0.04) 0.92 ns  - 
C6:1 (Hexenoylcarnitine) 0.01  (0.007 – 0.01) 
0.009 
 (0.006 – 0.01) 1.43 ns  - 
C7-DC (Pimelylcarnitine) 0.03  (0.02 – 0.06) 
0.03 
 (0.01 – 0.05) 2.16 0.03 0.07 
C8 (Octanoylcarnitine) 0.14  (0.10 – 0.33) 
0.12 
 (0.07 – 0.42) 1.18 ns  - 
C9 (Nonaylcarnitine) 0.05  (0.03 – 0.08) 
0.06 
 (0.04 – 0.09) 1.83 ns  - 
Hexose 4291.50  (2802 – 5918) 
4054.50 
 (2846 – 7189) 0.93 ns  - 
 
Z-values according to Wilcoxon matched pairs test (FEP patients before AP treatment 
compared to FEP patients after 7-month AP treatment).  
a High-sensitive biochip array technology was used to measure levels of cytokines. 
b Metabolic biochip array technology was used to measure metabolic markers. 





Table A-3. Identification of differences in serum cytokines, growth factor, metabolic 
biomarkers (pg/mL), and acylcarnitine levels (µmoles) between the first-episode psychosis 














(Ƞ2) Median       
(min–max) 
Median       
(min–max) 
Inflammatory markers and growth factor
IL (Interleukin)-1αa 0.15 (0.08 – 1.26) 
0.16 
(0.06 – 0.60) -0.65 ns - 
IL (Interleukin)-1αb 0.24 (0 – 1.77) 
0.32 
(0.20 – 1.67) -2.89 0.004 0.12 
IL-1βa 1.21 (0.40 – 3.39) 
1.91 
(0.45 – 4.47) -3.35 0.0008 0.16 
IL-2a 2.06 (1.14 – 3.34) 
2.81 
(1.34 – 4.49) -4.55 5E-6 0.28 
IL-4a 1.35 (0.92 – 4.32) 
1.30 
(0.96 – 2.84) 0.33 ns - 
IL-6a 0.60 (0.19 – 2.27) 
0.60 
(0.13 – 1.93) 0.79 ns - 
IL-6b 0.75 (0.23 – 1.64) 
0.53 
(0.23 – 1.54) 1.74 ns - 
INF (Interferon)-γ a 0.21 (0.17 – 0.69) 
0.30 
(0.19 – 0.53) -3.07 0.002 0.13 
TNF (Tumor necrosis factor)- αa 1.71 (1.03 – 2.82) 
1.70 
(0.86 – 8.70) -0.31 ns - 
TNF (Tumor necrosis factor)- αb 5.10 (2.84 – 9.30) 
5.17 
(3.42 – 8.73) 0.31 ns - 
PAI (Plasminogen  
activator inhibitor)-1b 
22.01 
(7.06 – 57.07) 
21.35 
(7.57 – 49.88) 0.79 ns - 
Ferritinb 30.9 (4.75 – 150.0) 
22.1 
(1.22 – 184.7) 1.04 ns - 
EGF  
(Epidermal growth  
factor)a 
1.68 
(0.49 – 7.74) 
2.05 
(0.66 – 7.74) -1.12 ns - 
Metabolic protein markersb 
Insulin 10.10 (3.03 – 66.81) 
8.47 
(1.80 – 126.9) 0.83 ns - 
C-peptide 1.90 (0.28 – 7.71) 
1.20 
(0.37 – 2.28) 2.32 0.02 0.08 
Leptin 1.21 (0 – 9.29) 
1.41 
(0.38 – 6.69) -0.07 ns - 
Resistin 2.80 (1.42 – 4.76) 
2.66 
(1.59 – 4.10) 1.22 ns - 
Adiponectin 5591 (1084 –10223) 
7076 














(Ƞ2) Median       
(min–max) 
Median       
(min–max) 
Acylcarnitinesc 
C0 (Carnitine) 30.35 (15.80 – 58.40) 
32.20  
(17.30 – 52.70) -0.81 ns - 
C10 (Decanoylcarnitine) 0.22 (0.12 – 1.08) 
0.28 
(0.15 – 0.45) -1.23 ns - 
C10:1 (Decenoylcarnitine) 0.13 (0.06 – 0.31) 
0.134 
(0.08 – 0.23) -0.01 ns - 
C10:2 (Decadienylcarnitine) 0.05 (0.04 – 0.10) 
0.06 
(0.04 – 0.10) -1.65 ns - 
C12 (Dodecanoylcarnitine) 0.09 (0.04 – 0.28) 
0.11 
(0.06 – 0.18) -1.05 ns - 
C12-DC (Dodecanedioylcarnitine) 0.12 (0.10 – 0.16) 
0.12 
(0.11 – 0.14) -0.01 ns - 
C12:1 (Dodecenoylcarnitine) 0.12 (0.05 – 0.27) 
0.12  
(0.07 – 0.19) -0.24 ns - 
C14 (Tetradecanoylcarnitine) 0.02 (0.01 – 0.04) 
0.03 
(0.01 – 0.04) -1.27 ns - 
C14:1 (Tetradecenoylcarnitine) 0.038 (0.02 – 0.16) 
0.04 





(0.01 – 0.03) 
0.02 
(0.01 – 0.02) -0.80 ns - 
C14:2 (Tetradecadienylcarnitine) 0.02 (0.01 – 0.04) 
0.02 





(0.01 – 0.02) 
0.01 
(0.01 – 0.02) -1.70 ns - 
C16 (Hexadecanoylcarnitine) 0.08 (0.04 – 0.15) 
0.09  




(0.01 – 0.03) 
0.01 
(0.01 – 0.03) 0.76 ns - 
C16:1 (Hexadecenoylcarnitine) 0.02 (0.01 – 0.05) 
0.02 




(0.01 – 0.02) 
0.01  
(0.01 – 0.02) 0.38 ns - 
C16:2 (Hexadecadienylcarnitine) 0.01 (0.01 – 0.02) 
0.01 




(0.02 – 0.04) 
0.03  
(0.02 – 0.04) -0.56 ns - 
C18 (Octadecanoylcarnitine) 0.04 (0.02 – 0.06) 
0.04 
(0.02 – 0.07) 0.26 ns - 
C18:1 (Octadecenoylcarnitine) 0.08 (0.04 – 0.17) 
0.09  














(Ƞ2) Median       
(min–max) 





(0.01 – 0.05) 
0.02  
(0.01 – 0.05) -0.53 ns - 
C18:2 (Octadecadienylcarnitine) 0.03 (0.02 – 0.05) 
0.03  
(0.01 – 0.05) -0.39 ns - 
C2 (Acetylcarnitine) 4.11 (2.24 – 7.72) 
3.96  
(1.78 – 5.96) 0.69 ns - 
C3 (Propionylcarnitine) 0.30 (0.14 – 0.62) 
0.31  




(0.03 – 0.07) 
0.04 





(0.05 – 0.12) 
0.06  




(0.03 – 0.07) 
0.04  
(0.03 – 0.05) -1.13 ns - 
C3:1 (Propenoylcarnitine) 0.03 (0.02 – 0.06) 
0.03 
(0.02 – 0.04) -0.45 ns - 
C4 (Butyrylcarnitine) 0.17 (0.10 – 0.31) 
0.18 
(0.12 – 0.30) -1.71 ns - 
C4:1 (Butenylcarnitine) 0.05 (0.03 – 0.07) 
0.05 





(0.01 – 0.06) 
0.03 
(0.02 – 0.04) -0.58 ns - 
C5 (Valerylcarnitine) 0.16 (0.10 – 0.39) 
0.17  





(0.01 – 0.04) 
0.02 




 (0.02 – 0.05) 
0.04 
(0.03 – 0.06) -0.64 ns - 
C5:1 (Tiglylcarnitine) 0.07  (0.04 – 0.12) 
0.08 
(0.05 – 0.12) -0.83 ns - 
C5:1-DC (Glutaconylcarnitine) 0.02  (0.01 – 0.04) 
0.03 
(0.02 – 0.04) -0.08 ns - 
C6:1 (Hexenoylcarnitine) 0.009  (0.006 – 0.01) 
0.009 
(0.006 – 0.01) -1.40 ns - 
C7-DC (Pimelylcarnitine) 0.03  (0.01 – 0.05) 
0.03 
(0.02 – 0.04) -1.49 ns - 
C8 (Octanoylcarnitine) 0.12  (0.07 –0.42) 
0.13 
(0.09 – 0.20) -1.11 ns - 
C9 (Nonaylcarnitine) 0.06  (0.04 – 0.09) 
0.06 














(Ƞ2) Median       
(min–max) 
Median       
(min–max) 
Hexose 4054.50  (2846 – 7189) 
3907.00 
(2335– 5533) 1.68 ns - 
 
Z-adjusted values according to Mann-Whitney U-test (FEP patients after 7-month AP 
treatment compared to CSs).  
a High-sensitive biochip array technology was used to measure levels of cytokines. 
b Metabolic biochip array technology was used to measure metabolic markers. 
c Serum level of ACs and hexoses were determined with the AbsoluteIDQ™ p180 kit. 
 
 
Table A-4. Inflammatory marker valuesa (pg/mL) of patients with schizophrenia (SCH) 
spectrum disorder compared to control subjects (CSs) 
 
 
SCH patients CSs 









Pro-inflammatory cytokines  
IL (Interferon)-1α  0.07 (0.03 – 1.13)   0.09 (0.04 – 0.35) -1.46 ns - 
IL-1β   0.57 (0.21 – 11.46) 0.54 (0.34 – 1.67)  -0.26 ns - 
IL-2  2.18 (0.80 – 8.10) 1.21 (0.47 – 2.97) 8.78 <1E-6 0.31 
IL-6  1.80 (0.38 – 28.20) 0.89 (0.33 – 2.29) 8.01 <1E-6 0.26 
IL-8  9.90 (2.27 – 65.50) 6.63 (3.20 – 13.10) 6.14 <1E-6 0.15 
MCP-1  244.8 (42.75 – 741.9) 165.3 (26.90 – 345.2) 6.98 <1E-6 0.19 
TNF (Tumor 
necrosis factor)-α  3.23 (1.39 – 8.71) 3.38 (1.30 – 6.54) -1.67 ns 
- 
IFN (Interferon)-γ  4.12 (0.41 – 38.87) 1.23 (0.16 – 4.10) 9.93 <1E-6 0.40 
Anti-inflammatory cytokines 
IL-4   1.25 (0.58 – 5.04) 1.44 (0.46 – 2.83) -3.18 0.002 0.04 
IL-10 0.77 (0.21 – 7.46)  0.55 (0.20 – 1.32)  6.27 <1E-6 0.16 
Ratio of biomarkers
INF-γ/IL-4  3.09 (0.38 – 21.24) 0.75 (0.12 – 4.82) 9.63 <1E-6 0.37 
INF-γ/IL-10 4.35 (0.34 – 56.23) 2.00 (0.15 – 12.71) 6.26 <1E-6 0.16 
IL-2/INF-γ 0.60 (0.09 – 6.24) 1.14 (0.24 – 7.09) -5.61 <1E-6 0.13 
Growth factors  
VEGF (Vascular  
 endothelial growth  
 factor) 
119.4 (12.62 – 739.5) 115.9 (14.14 – 306.8) 2.06 0.04 0.02 
EGF (Epidermal    
 growth factor) 55.26 (2.64 – 170.64) 47.60 (3.57 – 101.00) 1.98 0.048 0.02 
 
Z-adjusted values according to Mann-Whitney U-test.  
The table contains between groups difference data with effect size ≥ 0.10. 
a High-sensitive biochip array technology was used to measure levels of cytokines. 
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2. Quality control 
2.1. Cytokines, chemokines, and growth factors quantitation 




Level 1 Level 2 Level 3 
Conc pg/ml %CV Conc pg/ml %CV Conc pg/ml %CV 
IL (Interleukin)-1α 2.7 10.9 45.4 9.7 169.7 11.4 
IL-1ß 5.1 9.3 63.9 8.7 233.4 7.4 
IL-2 16.7 7.8 84.1 5.8 255.8 6.9 
IL-4 13.1 9.6 69.9 9.5 232.2 8.4 
IL-6 1.4 11.9 10.5 9.8 26.7 7.8 
IL-8 11.6 9.4 123.0 9.4 629.0 7.0 
IL-10 8.2 6.8 93.9 5.6 286.0 6.1 
IFN (Interferon)-γ 7.9 10.1 145.7 7.4 620.1 7.7 
TNF (Tumor necrosis factor)-α 9.4 7.1 111.8 7.2 486.1 12.7 
MCP (Plasminogen activator  
 inhibitor)-1 27.6 12.2 136.3 8.9 320.8 5.8 
VEGF (Vascular endothelial 
growth factor) 17.3 10.4 146.4 10.8 456.0 7.3 
EGF (Epidermal growth factor) 13.0 9.2 36.7 9.5 198.7 9.6 
 
Conc ‒ concentration; CV ‒ coefficient of variation. 
 
 


















IL (Interleukin)-1α 2.7 15.5 51.1 8.9 174.9 13.4 
IL-1ß 4.2 9.9 66.7 11.8 213.7 8.7 
IL-2 16.4 7.8 85.2 6.5 258.9 8.2 
IL-4 12.5 11.6 71.4 8.6 206.9 8.8 
IL-6 1.5 8.4 10.3 7.4 23.7 8.4 
IL-8 11.3 11.1 132.6 9.9 560.8 9.2 
IL-10 8.2 6.7 96.8 6.5 239.4 7.5 
IFN (Interferon)-γ 8.1 11.4 135.4 6.4 542.1 7.6 
TNF (Tumor necrosis factor)-α 9.9 8.6 116.5 6.7 442.1 7.0 
MCP (Plasminogen activator  
 inhibitor)-1 27.9 12.8 139.8 10.4 272.4 7.2 
VEGF (Vascular endothelial 
 growth factor) 17.4 12.0 135.2 7.2 395.7 10.7 
EGF (Epidermal growth factor) 13.1 11.7 38.9 8.5 181.2 9.6 
 
Conc ‒ concentration; CV ‒ coefficient of variation. 
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Table A-7. Sensitivity of cytokine assay 
 
Analyte Calibration range (pg/ml) Sensitivity (pg/ml) 
IL (Interleukin)-1α 0 – 225 0.19 
IL-1ß 0 – 1125 0.26 
IL-2 0 – 1200 0.90 
IL-4 0 – 1500 2.12 
IL-6 0 – 400 0.12 
IL-8 0 – 1450 0.38 
IL-10 0 – 450 0.37 
IFN (Interferon)-γ 0 – 500 0.44 
TNF (Tumor necrosis factor)-α 0 – 600 0.59 
MCP (Plasminogen activator inhibitor)-1 0 – 500 0.66 
VEGF (Vascular endothelial growth factor) 0 – 1000 1.53 




2.2. Metabolic and inflammatory biomarkers quantitation 
















C-peptide 6.9 5.6 5.4 7.9 8.6 12.2 
Ferritin 5.7 8.2 7.2 10.0 5.7 8.2 
Insulin 9.4 7.8 7.5 10.3 9.0 14.0 
IL (Interleukin)-1α 4.3 3.8 3.6 8.5 7.6 10.7 
IL-6 6.4 6.1 6.3 4.9 6.3 8.4 
Leptin 7.7 4.6 5.3 8.7 6.0 8.2 
PAI (Plasminogen activator 
inhibitor)-1 10.5 10.9 10.7 14.0 13.1 14.3 
Resistin 12.1 10.1 11.8 5.2 7.1 8.6 
TNF (Tumor necrosis 
factor)-α 6.1 6.3 5.5 9.2 7.4 7.9 
 





Table A-9. Units and sensitivity of metabolic and cytokine array. 
 
Analyte Units Sensitivity 
C-peptide ng/mL 0.21 
Ferritin ng/mL 3.27 
Insulin IU/mL 2.32 
IL (Interleukin)-1α pg/mL 0.77 
IL-6 pg/mL 0.73 
Leptin ng/mL 1.10 
PAI (Plasminogen activator inhibitor)-1 ng/mL 2.34 
Resistin ng/mL 1.06 
TNF (Tumor necrosis factor)-α pg/mL 0.66 
 
 
2.3. Adiponectin quantitation  
Table A-10. Intra-assay and inter-assay precision of adiponectin   
 
Analyte Intra-assay precision Inter-assay precision 
Sample  1  2  3  1  2  3  
Number of samples  20  20  20  40  40  40  
Mean (ng/mL)  19.8  69.9  143  20.5  74.4  157  
Standard deviation  0.50  2.40  6.76  1.40  4.30  10.8  
CV (%)  2.5  3.4  4.7  6.8  5.8  6.9  
 
CV ‒ coefficient of variation. 
 
 
Intra-assay precision (precision within an assay): three samples of known concentration 
were tested on one plate to assess intra-assay precision. Inter-assay precision (precision 
between assays): three samples of known concentration were tested in separate assays to 
assess inter-assay precision.  
Sensitivity. The minimum detectable dose of human adiponectin ranged from 0.079-
0.891 ng/mL. The mean minimum detectable dose was 0.246 ng/mL. The minimum 
detectable dose was determined by adding two standard deviations to the mean optical 
density value of twenty zero standard replicates and calculating the corresponding 
concentration. 
 
2.4. Acylcarnitine quantitation  
Biocrates AbsoluteIDQ™ p180 kit (Biocrates Life Sciences AG, Innsbruck, Austria) 
enables the measurement of 188 endogenous metabolites and 45 metabolite ratios using 
a combination of flow injection analysis and liquid chromatograph tandem mass 
spectrometry technique. The assay allows simultaneous quantification of 188 
metabolites, including 40 ACs. The kit has been validated according to the Food and 
Drug Administration guidelines and Biocrates company holds an ISO 9001:2008 
certification of quality. ACs, and hexose were quantified by their relative intensity over 
the chosen isotopically labeled internal standard. In addition, 3 quality control standards 
are measured to ensure the normalization of signal intensities during inter-plate 
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measurements. The metabolite concentrations were calculated linearly using a 
combination of Analyst (ABSciex, Framingham, USA) and MetIDQ (Biocrates Life 
Sciences AG, Innsbruck, Austria) software. Due to lack of isotopic standards for lipids 
and ACs in the flow-injection analysis mode the results are classified as semi-
quantitative. 
Limits of detection. The absolute minimum limit of detection (LOD) for a metabolite 
is largely dependent on the sensitivity of the mass-spectrometer and the ionization of a 
metabolite. LODs, lower limit of quantification (LLOQ) and upper limit of 
quantification (ULOQ) for selected metabolites are given in Table A-11. 
 
 
Table A-11. Acylcarnitine quantitation 









C0 Carnitine X  4 5 120 
C10  Decanoylcarnitine X  0.16 0.3 6 
C10:1 Decenoylcarnitine  X 0.12   
C10:2 Decadienylcarnitine  X 0.04   
C12 Dodecanoylcarnitine X  0.057 0.4 12 
C12-DC Dodecanedioylcarnitine  X 0.2   
C12:1 Dodecenoylcarnitine  X 0.2   
C14 Tetradecanoylcarnitine X  0.03 0.4 6 
C14:1 Tetradecenoylcarnitine  X 0.015   
C14:1-OH Hydroxytetradecenoylcarnitine  X 0.015   
C14:2 Tetradecadienylcarnitine  X 0.012   
C14:2-OH Hydroxytetradecadienylcarnitine  X 0.015   
C16 Hexadecanoylcarnitine X  0.018 0.4 12 
C16-OH Hydroxyhexadecanoylcarnitine  X 0.015   
C16:1 Hexadecenoylcarnitine  X 0.06   
C16:1-OH Hydroxyhexadecenoylcarnitine  X 0.02   
C16:2 Hexadecadienylcarnitine  X 0.008   
C16:2-OH Hydroxyhexadecadienylcarnitine  X 0.03   
C18 Octadecanoylcarnitine X  0.02 0.4 6 
C18:1 Octadecenoylcarnitine  X 0.04   
C18:1-OH Hydroxyoctadecenoylcarnitine  X 0.023   
C18:2 Octadecadienylcarnitine  X 0.009   
C2 Acetylcarnitine X  0.15 0.4 35 





(Hydroxybutyrylcarnitine  X 0.09   
C5- Hydroxyvalerylcarnitine  X 0.1   
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C3-OH Hydroxypropionylcarnitine  X 0.05   
C3:1 Propenoylcarnitine  X 0.03   
C4 Butyrylcarnitine X  0.03 0.4 12 
C4:1 Butenylcarnitine  X 0.03   
C6(C4:1-
DC) Hexanoylcarnitine (Fumarylcarnitine) X  0.08 0.2 6 





(Hydroxyhexanoylcarnitine)  X 0.035   
C5-M-DC Methylglutarylcarnitine  X 0.06   
C5:1 Tiglylcarnitine  X 0.04   
C5:1-DC Glutaconylcarnitine  X 0.015   
C6:1 Hexenoylcarnitine  X 0.035   
C7-DC Pimelylcarnitine  X 0.035   
C8 Octanoylcarnitine X  0.17 0.2 8 
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